Composition for preventing or treating skin aging
Oral estetrol administration addresses the challenges of hypoestrogenism-related skin aging by improving skin quality and reducing aging signs through enhanced keratinocyte and fibroblast activity, offering a more effective and side-effect-reduced treatment for menopausal skin issues.
Patent Information
- Application Number
- JP2024531577
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-29
- Filing Date
- 2022-11-29
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current methods for treating the effects of hypoestrogenism on the skin, such as those associated with menopause, often result in undesirable side effects and are not optimally effective in preventing or reversing skin aging, particularly due to hormonal imbalances.
Oral administration of estetrol in specific dosage ranges to achieve clinically relevant concentrations in the skin, affecting both epidermal keratinocytes and dermal fibroblasts, thereby improving skin quality and reducing aging signs.
Estetrol effectively improves skin quality by enhancing keratinocyte migration and proliferation, fibroblast growth, providing antioxidant and anti-inflammatory effects, and reducing signs of skin aging, including fine lines, wrinkles, and inflammation.
Smart Images

Figure 2024544619000013 
Figure 2024544619000014 
Figure 2024544619000015
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions comprising an estetrol component for the prevention or treatment of the effects of hypoestrogenism in the skin, cosmetic or therapeutic treatments in which such compositions are used, and related formulations and dosage units.
[0002] As described in more detail herein, this treatment demonstrates statistically significant efficacy coupled with a favorable side effect profile when compared to currently available methods for preventing or treating the effects of hypoestrogenism in the skin and the reported side effects. [Background technology]
[0003] Skin is the most voluminous and most visible organ of the body, and as people age, it shows visible signs of aging. Cosmetics and preparations intended to prevent or reverse skin aging account for a significant portion of the daily living expenses of many people, which means that research attention into skin aging and means of controlling this phenomenon is maintained and even encouraged. Skin aging is manifested in various ways, but usually includes, but is not limited to, wrinkles, loss of elasticity, and roughness. These manifestations are caused by many different factors, including changes at the skin cell level, and structural and functional changes in extracellular matrix components such as collagen, elastin, and proteoglycans. Each of these is necessary, for example, to maintain sufficient tensile strength, elasticity, maintenance of proper skin barrier function, and moisture retention of the skin. Intrinsic skin aging is generally associated with physiological aging processes, including hormonal changes, decreased cell proliferation, oxidative stress, inflammation, etc., which cause thinner and drier skin, wrinkling (i.e., the occurrence of skin cracking or pitting), and gradual dermal atrophy. Extrinsic skin aging is caused by external environmental factors such as exposure to ultraviolet radiation from the sun, air pollution, smoking, nutritional deficiencies, etc. In reality, they are often interrelated and / or form a synergistic feedback loop. For example, ultraviolet radiation ultimately induces reactive oxygen species (ROS). Vice versa, the thinner the skin, the more sensitive it is to ultraviolet radiation. The focus of the present invention is on preventing or reducing the effects of intrinsic skin aging and extrinsic skin aging caused, for example, by ultraviolet radiation exposure and / or air pollution.
[0004] One particular aspect that is important to note in this regard is the influence of hormone balance in women, such as during or around the menopausal transition and early postmenopause (perimenopause). It should be noted that the influence of hormone balance may persist after the perimenopausal period, i.e. in postmenopausal women, often referred to as menopausal women. This change in hormone balance may affect the composition of the skin and its proper functioning. It has been reported that a decrease in circulating sex hormones, such as estrogen, adversely affects the skin and skin-related functions (Non-Patent Document 1). Thereby, effects on wound healing, the composition and structural integrity of the dermal extracellular matrix, and the elasticity and fragility of the skin under friction and pressure are described. Thus, beyond the cosmetic aspect of maintaining youthful skin, in certain subjects, age-related skin changes lead to conditions requiring medical treatment, resulting in substantial medical costs. As previously reported, topical application of compositions containing estrogens, such as estradiol (E2) or estetrol (E4), to the skin has been widely studied. For example, Patent Document 1 reports the topical application of a cosmetic composition containing estetrol. Similarly, Non-Patent Documents 2 and 3 discuss the effects of topical administration of estrogen to the skin.
[0005] Additionally, non-hormonal receptor agonists (NERAs), such as MEP, are being investigated for use in treating skin aging associated with menopause. NERAs are interesting because they do not have the side effects of true hormones, such as estradiol itself.
[0006] Oral (systemic) administration of hormone replacement therapy including estrogen is usually not considered the best option for cosmetic applications, for example, against skin aging, but it is an interesting route because it avoids the need to apply creams or the like to the skin every day, which can be a bothersome and / or unpleasant experience for some subjects. Another advantage is that the symptoms associated with menopause can be simultaneously alleviated by systemic use of estrogen at a certain dose. However, one long-standing concern with this form of administration is the need to avoid side effects associated with such systemic administration or the accumulation of estrogen in the subject. For example, Patent Document 1 describes that topical application of estrogen is preferred for treating the skin. Conversely, this document describes that menopausal symptoms should be treated separately by oral or subcutaneous administration. It was also suggested that the proposed dosage should be lower than that for suppressing symptoms of hypoestrogenism.
[0007] Therefore, there remains a need to develop new compositions or formulations that overcome some of these identified problems. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] PCT Application International Publication No. 03 / 103685 [Non-patent literature]
[0009] [Non-Patent Document 1] Stevenson and Thornton, Clin Interv Aging, 2007 [Non-Patent Document 2] Creidi et al. "Effect of a conjugated estrogen cream on aging facial skin", Maturitas, (1994)19, p. 211 [Non-Patent Document 3] Shah et al. "Estrogenand skin. An overview", Am J Clin Dermatol (2001); 2 (3): 143-150 Summary of the Invention
[0010] Against this background, the inventors have now surprisingly found that oral administration of estetrol in a specific dosage range may be beneficial in preventing or treating skin ageing associated with or resulting from hormonal imbalance during perimenopause and menopause.
[0011] Unexpectedly, it has been shown that estetrol reaches clinically relevant concentrations in the skin after oral administration. Furthermore, the inventors have been able to show that estetrol acts on both epidermal keratinocytes and dermal fibroblasts. From these findings arise many beneficial effects for preventing or reducing skin aging, ranging from influencing keratinocyte migration and proliferation, fibroblast growth, to anti-inflammatory effects beyond antioxidant effects. This opens up the opportunity to provide oral formulations or dosage units that can be used to prevent, reduce skin aging, and improve or maintain overall skin quality and / or skin appearance. Furthermore, this new knowledge provides innovative therapeutic strategies for skin-related disease profiles, such as, but not limited to, psoriasis and dermatoporosis.
[0012] In the following numbered paragraphs, some specific embodiments of the present invention are described.
[0013] 1. An oral dosage unit comprising an estetrol component in an amount equivalent to about 10 mg to about 25 mg of estetrol (E4), for use in improving or maintaining skin quality and / or skin appearance, preferably for use in maintaining skin quality and / or skin appearance or for use in preventing or treating skin aging.
[0014] 2. Use of an estetrol component in an oral daily dose equivalent to about 10 mg to about 25 mg of estetrol in the manufacture of a medicament for improving or maintaining skin quality and / or skin appearance or for use in the prevention or treatment of skin aging, preferably for maintaining skin quality and skin appearance.
[0015] 3. A method for improving or maintaining skin quality and / or skin appearance, preferably for maintaining skin quality and / or skin appearance or for use in preventing or treating skin aging, comprising oral administration (or oral ingestion) of an estetrol component in a daily amount equivalent to about 10 mg to about 25 mg of estetrol.
[0016] 4. A cosmetic method for improving or maintaining skin quality and / or skin appearance, preferably for maintaining skin quality and / or skin appearance or for use in preventing or treating skin aging, comprising oral administration (or oral ingestion) of an estetrol composition in a daily amount corresponding to about 10 mg to about 25 mg of estetrol.
[0017] 5. Improving or maintaining skin quality and / or skin appearance to eliminate or reduce the appearance of uneven pigmentation (i.e., changes in melanin), redness (i.e., erythema or visible hemoglobin), dullness / sallowness (i.e., lack of radiance; yellow or grayish undertone), brightness (i.e., ability of skin to "shine" or reflect light), oiliness / shininess (i.e., excess sebum on the skin's surface), dryness (i.e., lack of moisture; dehydration), fine lines (i.e., light wrinkles), coarse wrinkles, and 5. The oral dosage unit for use according to aspect 1, the use according to aspect 2, the method of treatment according to aspect 3, or the method according to aspect 4, wherein one or more attributes selected from the group consisting of: fine lines (i.e. deep wrinkles), pores (i.e. surface landmarks of the pilosebaceous unit), crepiness (i.e. fine cigarette paper wrinkles in the skin), hydration (i.e. water content; wetness), laxity (i.e. loose skin), elasticity / softness (i.e. resilience to palpation), firmness (i.e. ability to stretch), thickness (i.e. density of the epidermis and dermis), and roughness are improved or maintained.
[0018] 6. The oral dosage unit, use, or method according to any one of aspects 1-5, wherein improving or maintaining skin quality and / or skin appearance comprises reducing the signs of skin aging, reversing the signs of skin aging, and / or reducing the signs of skin aging.
[0019] 7. The oral dosage unit for use, use, or method according to aspect 6, wherein said skin aging is characterized by reduced skin moisturization, reduced skin elasticity, increased moisture loss, reduced skin roughness, reduced epidermal thickness, reduced dermal thickness, and reduced sebum content.
[0020] 8. An oral dosage unit for use, use, or method according to aspect 6 or 7, wherein said skin aging is assessed using one or more of the following parameters: dryness, tightness, desquamation, sagging, telangiectasia, turgor, firmness, elasticity, moisture content, sebum production (stickiness), vascularization, and pigmentation.
[0021] 9. An oral dosage unit for use, a use or a method according to any one of aspects 5 to 8, wherein said skin aging is hormone-related skin aging, more preferably skin aging caused by menopausal hormone deregulation, such as estrogen deficiency (synonymously referred to as the term hypoestrogenism).
[0022] 10. The oral dosage unit for use, the use or the method according to any one of aspects 1-9, wherein the subject is at least 40 years old, preferably at least 45 years old, preferably at least 50 years old, preferably at least 55 years old, more preferably at least 60 years old, most preferably at least 65 years old.
[0023] 11. An oral dosage unit for use, use or method according to any one of aspects 1 to 10 in a subject diagnosed with or considered to be suffering from dermatoporosis.
[0024] 12. The oral dosage unit for use, use, or method according to aspect 11, wherein the skin porous disease is characterized by decreased expression of collagen I, decreased expression of collagen III, decreased expression of collagen IV, increased expression of matrix metalloproteinase 1, increased expression of matrix metalloproteinase 2, increased expression of matrix metalloproteinase 3, decreased expression of matrix metalloproteinase I, decreased elastic tissue, defective collagen synthesis by fibroblasts, decreased hyaluronic acid, or any combination thereof.
[0025] 13. An oral dosage unit for use, use or method according to any one of aspects 1 to 12, wherein said improvement or maintenance of skin quality and / or skin appearance is obtained by increasing keratinocyte function and / or growth in the skin, e.g. the epidermis.
[0026] 14. An oral dosage unit for use, use, or method according to any one of aspects 1 to 13, wherein said improving or maintaining skin quality and / or skin appearance increases fibroblast function, migration, and / or fibroblast growth in the skin, or stimulated epithelial-mesenchymal interaction (EMI).
[0027] 15. An oral dosage unit for use, use or method according to any one of aspects 1 to 14, wherein said improvement or maintenance of skin quality and / or skin appearance is characterized by any one or more effects selected from the group including increased moisturization of the skin, e.g. by increasing the level of glycosaminoglycans (particularly hyaluronic acid) in the skin and increasing hyaluronic acid synthase activity; increased sebum levels; and improved skin barrier function.
[0028] 16. An oral dosage unit for use, use or method according to any one of aspects 1 to 15, wherein said improving or maintaining skin quality and / or skin appearance is characterized by improved wound healing and / or reduced skin inflammation.
[0029] 17. An oral dosage unit for use, use or method according to any one of aspects 1 to 16, wherein said improving or maintaining skin quality and / or skin appearance is characterized by any one or more effects selected from the group comprising reducing oxidative stress, e.g. by reducing ROS levels in the skin, and mitigating uneven skin pigmentation, such as the appearance of age spots.
[0030] 18. The oral dosage unit for use, use or method according to any one of aspects 1 to 17, wherein said improving or maintaining skin quality and / or skin appearance is characterized by a reduction in any one or more effects selected from the group consisting of acne (pimples), skin rash and pruritus.
[0031] 19. An oral dosage unit for use, use or method according to any one of aspects 1 to 18, wherein said improving or maintaining skin quality and / or skin appearance is characterized by a reduction in inflammatory markers, preferably a reduction in interleukin-6 (IL-6) release.
[0032] 20. An oral dosage unit for use, use or method according to aspect 19, wherein IL-6 release is reduced when compared to IL-6 release in a control condition when the subject is treated with an estrogen that is not estetrol.
[0033] 21. An oral dosage unit for use, a use, or a method according to aspect 20, wherein the estrogen that is not estetrol is estradiol.
[0034] 22. An oral dosage unit for use, a use or a method according to any one of aspects 19 to 21, wherein the reduction in IL-6 release is at least 10%, preferably at least 20%, more preferably at least 30%, most preferably at least 40% when compared to a control condition when the subject is treated with an estrogen that is not estetrol, and preferably the estrogen that is not estetrol is estradiol.
[0035] 23. An oral dosage unit for use, use or method according to any one of aspects 1 to 22, wherein said improving or maintaining skin quality and / or skin appearance is characterized by prevention or reduction of symptoms of psoriasis in menopausal women.
[0036] 24. An oral dosage unit for use, use or method according to any one of aspects 1 to 23, wherein a daily amount equivalent to about 14 mg to about 21 mg of estetrol, preferably about 14 mg to about 16 mg or about 19 mg to about 21 mg of estetrol, is administered.
[0037] 25. An oral dosage unit for use, use, or method according to any one of aspects 1 to 24, wherein the estetrol component is present in the oral dosage unit in an amount equivalent to about 14 mg to about 16 mg of estetrol, or the estetrol component is administered in an amount equivalent to about 14 mg to about 16 mg of estetrol.
[0038] 26. An oral dosage unit for use, use, or method according to any one of aspects 1 to 25, wherein the estetrol component is estetrol or an ester thereof.
[0039] 27. An oral dosage unit for use, use, or method according to any one of aspects 1 to 26, wherein the estetrol component is estetrol monohydrate.
[0040] 28. An oral dosage unit for use, a use, or a method according to any one of aspects 1 to 27, wherein said dosage unit does not contain a progestogen, or no progestogen is used or is not co-administered.
[0041] 29. An oral dosage unit, use, or method for use according to any one of aspects 1 to 28, wherein a progestogen is present in, used in, or is co-administered with or administered after treatment with estetrol.
[0042] 30. The oral dosage unit for use, use, or method according to aspect 29, wherein the progestogen is selected from the group comprising progesterone, drospirenone, norethisterone, norethisterone-acetate (NETA), dydrogesterone, levonorgestrel (LNG), etonogestrel, norgestrel, nomegestrol, nomegestrol-acetate (NOMAC), trimegestone, nestorone, dydrogesterone, gestodene, desogestrel, norgestimate, cyproterone acetate, dienogest, and chlormadinone. In a preferred embodiment, the progestogen is selected from the group comprising drospirenone, progesterone, or dydrogesterone.
[0043] 31. An oral dosage unit, use or method for use according to aspect 29 or 30, wherein the progestogen is present in the oral dosage unit in an amount equivalent to about 0.25 mg to about 4 mg, such as about 1 mg to about 4 mg, more preferably about 1 mg to about 3 mg, such as about 2.5 mg to 3.5 mg of drospirenone, or the progestogen is administered in an amount equivalent to about 2.5 mg to 3.5 mg of drospirenone. In a preferred embodiment, the progestogen is drospirenone.
[0044] 32. The oral dosage unit, use or method for use according to aspect 29 or 30, wherein said progestogen is present in said oral dosage unit in an amount equivalent to about 1 mg to 20 mg of progesterone, or said progestogen is administered in an amount equivalent to about 5 mg to 10 mg of progesterone. In a preferred embodiment, said progestogen is progesterone.
[0045] 33. The oral dosage unit, use, or method for use according to aspect 29 or 30, wherein the progestogen is present in the oral dosage unit in an amount equivalent to about 25 mg to 300 mg of dydrogesterone, or the progestogen is administered in an amount equivalent to about 100 mg to 200 mg of dydrogesterone. In a preferred embodiment, the progestogen is dydrogesterone.
[0046] 34. An oral dosage unit for use, a use or a method according to any one of aspects 1 to 33, wherein a further active ingredient known in the art suitable for improving or maintaining skin quality and / or skin appearance or for preventing or treating skin aging is present in the oral dosage unit or a further active ingredient suitable for preventing or treating skin aging is co-administered or administered before or after treatment with estetrol.
[0047] 35. The oral dosage unit or method for use according to any one of aspects 1-34, wherein the composition is formulated as an oral dosage unit.
[0048] 36. An oral dosage unit or method for use according to any one of aspects 1-35, wherein the composition is formulated for oral, sublingual, buccal, or labial administration.
[0049] 37. An oral dosage unit or method for use according to any one of aspects 1 to 36, wherein the oral dosage unit is formulated to correspond to a daily dosage unit or is administered as a daily dosage unit, respectively.
[0050] 38. In any one of the embodiments defined herein, the dosage units can be presented as a kit-of-parts, including packaging units (e.g., blister packs) containing daily oral dosage units with the estetrol component. The skilled artisan further knows that within the scope of the present invention, each packaging unit (e.g., blister pack) can be numbered or otherwise marked. Within the scope of the present invention, each packaging unit can be a sealed blister pack with a cardboard, paperboard, foil plastic backing and housed in a suitable cover.
[0051] In any one of the aspects defined herein, a packaging unit such as a bottle is also envisioned. The material of the bottle is not particularly limited. In a preferred embodiment, the bottle is a glass bottle characterized by a color that can reduce or prevent deterioration of the contents of the bottle, for example, by ultraviolet light, while maintaining a degree of transparency that allows visual inspection of the contents of the bottle. Suitable colors include, but are not limited to, amber, cobalt, or vintage green.
[0052] 39. In certain embodiments of the kit of parts according to aspect 38, the packaging unit comprises 28 containers, or a multiple of 28 containers (e.g., 2 to 12 times 28 containers).
[0053] The above numbered aspects are further described in the following sections and in the appended claims, the subject matter of which is hereby incorporated with particularity.
Brief Description of the Drawings
[0054] [Figure 1] It is a diagram showing the percentage of cell-free areas covered by normal human epidermal keratinocytes (NHEK) after contact with estetrol (E4) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). The results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). A Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: Cell-free area coverage after 6-hour contact. Right condition: Cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E4 10-7 M + MMC; E4 10-8 M + MMC; E4 10-9 M + MMC; E4 10-10 M + MMC. [Diagram 2] It is a diagram showing the percentage of cell-free areas covered by normal human epidermal keratinocytes (NHEK) after contact with estetrol (E4) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). The results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). A Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: Cell-free area coverage after 6-hour contact. Right condition: Cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E4 10-7 M; E4 10-8 M; E4 10-9 M; E4 10-10 M. [Diagram 3]Figure showing the percentage of cell-free areas covered by normal human epidermal keratinocytes (NHEK) after contact with β-estradiol (E2) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E2 10-7 M + MMC; E2 10-8 M + MMC; E2 10-9 M + MMC; E2 10-10 M + MMC. [Figure 4] Figure showing the percentage of cell-free areas covered by normal human epidermal keratinocytes (NHEK) after contact with β-estradiol (E2) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E2 10-7 M; E2 10-8 M; E2 10-9 M; E2 10-10 M. [Diagram 5]Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with estetrol (E4) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E4 10-7 M + MMC; E4 10-8 M + MMC; E4 10-9 M + MMC; E4 10-10 M + MMC. [Figure 6] Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with estetrol (E4) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). Results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-test was performed to compare the effect of the treatment against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: cell-free area coverage after 6-hour contact. Right condition: cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E4 10-7 M; E4 10-8 M; E4 10-9 M; E4 10-10 M. [Figure 7]Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with β-estradiol (E2) applied at four concentrations for different times in the presence of the growth inhibitor mitomycin C (MMC). The results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-tests were performed to compare the effect of the treatments against 0.1% ethanol + MMC. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: Cell-free area coverage after 6-hour contact. Right condition: Cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL) + MMC; E2 10-7 M + MMC; E2 10-8 M + MMC; E2 10-9 M + MMC; E2 10-10 M + MMC. [Figure 8] Figure showing the percentage of cell-free area covered by normal human dermal fibroblasts (NHDF) after contact with β-estradiol (E2) applied at four concentrations for different times in the absence of the growth inhibitor mitomycin C (MMC). The results are expressed as the percentage of cell-free area coverage relative to the 0-hour time point (mean ± standard deviation of three independent cultures). Student's t-tests were performed to compare the effect of the treatments against 0.1% ethanol. A p-value of 0.01 < p < 0.05 is considered significant, 0.001 < p < 0.01 is highly significant, and p < 0.001 is very highly significant. Left condition: Cell-free area coverage after 6-hour contact. Right condition: Cell-free area coverage after 24-hour contact. For each time point, from left to right: EtOH control (CTL); E2 10-7 M; E2 10-8 M; E2 10-9 M; E2 10-10 M. [Figure 9]Figure 1. Effect of estrogen on fibroblast migration in scratch assay. Pilot experiments suggest that E4 promotes fibroblast migration to the same extent as E2 in both mouse (A) and human (B) fibroblasts. The upper panel shows representative images of wound closure in the presence of vehicle, E2 (10-7 M) or E4 (10-7 M), and the lower panel shows the percentage of wound closure in the presence of vehicle, E2 or E4. 10-7 M E2 and 10-7 M E4 were tested in mouse fibroblasts (A), and five doses of both E2 and E4 (increasing from 10-10 M (left) to 10-6 M (right)) were tested in human fibroblasts (B). Data are presented as mean ± SEM of three independent cultures obtained from different donors. *: p<0.05. [Figure 10] Figure 1. Effect of estrogen on keratinocyte migration in a scratch assay. Under culture conditions supplemented with 15% human keratinocyte growth supplement (HKGS), the effect of E4 (10-10 M and 10-7 M) on keratinocytes appears to be higher than that of E2. X-axis: different test conditions (all concentrations expressed in M). Y-axis: percentage of wound closure. Dashed line: basal keratinocyte migration level observed for the control condition (leftmost condition; 10-7 M ethanol). [Figure 11] Figure 1 shows the effect of estrogen on immune cell polarization. Results are expressed as the relative expression of pro-inflammatory markers representing subtype M1 in (A) activated human monocytes treated with negative control (M1 vehicle), estradiol (M1 E2) or estetrol (M1 E4), and (B) non-activated mouse bone marrow-derived monocytes (BMDMs) treated with negative control (M0 vehicle), or activated mouse BMDMs treated with negative control (M1 vehicle), estradiol (M1 E2) or estetrol (M1 E4). Administration of E4 results in a switch of monocytes from subtype M1 (pro-inflammatory) to subtype M2 (healing). [Figure 12]Figure 1 shows the kinetics of treatment for induction of IL-6 and TNFA secretion from NHEKs and treatment with E2 or E4. After cell expansion, NHEKs were seeded in 24-well plates in complete medium. After 24 hours, E2 or E4 and controls (combined with pro-inflammatory stimuli) were applied for 24 hours in Epilife medium lacking hydrocortisone and phenol red. Supernatants were collected and stored at -20°C, and cell viability was assessed by MTS assay. [Figure 13] IL-6 release (normalized to viability data). Figure 1. Effect of E2 and E4 on PMA-induced IL-6 release from NHEKs. After cell expansion, NHEKs were seeded in 24-well plates with complete medium. After 24 hours, test articles and standards were applied for 24 hours in the presence of PMA and calcium ionophore A23187 in Epilife medium lacking hydrocortisone and phenol red. IL-6 release was assessed by ELISA and results were normalized to cell viability. Statistical analysis (Student's t-test) was performed to compare the effect of treatments to conditions treated with EtOH and stimulated with PMA / A23187 (*=compared to EtOH stimulated) or to controls stimulated with PMA / A23187 but not treated ($=compared to stimulated control (ctrl)). Y-axis: IL-6 release in culture medium of NHEKs (relative % to EtOH 0.1%, stimulated with PMA and Ca ionophore). [Figure 14] Figure 1. Experimental timeline and sample collection overview. A) Mini-osmotic pumps containing E2, E4 or vehicle are implanted on day 0. Non-invasive (ultrasound imaging and elasticity measurements) are performed on days 0, 5, 10 and 20. Mice are wounded on day 14. Study endpoint is day 21. B) Overview of skin aging measurements, from non-invasive ultrasound imaging to skin tension measurements. [Figure 15] In vitro assays to explore the mechanism of action: A) Immunofluorescence (confocal imaging) to quantify collagen 1 and collagen 3 deposition by FEC-stimulated HDFs. B) Zymography to quantify MMP2 activity in three samples (A-C) compared to an MMP standard. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0055] As used herein, the singular forms "a," "an," and "the" include both singular and plural referents unless the context clearly dictates otherwise.
[0056] The terms "comprising", "comprises" and "comprised of", as used herein, are synonymous with "including", "includes" or "containing" or "contains" and are inclusive or open-ended and do not exclude additional unrecited components, elements, or method steps. These terms also encompass "consisting of" and "consisting essentially of", which enjoy well-established meanings in patent terminology.
[0057] The recitation of numerical ranges by endpoints includes all values and fractions falling within the particular range, as well as the recited endpoints. This applies to numerical ranges whether the numerical range is introduced by the phrase "from to," or "between and," or otherwise.
[0058] The terms "about" or "approximately", as used herein, when referring to measurable values such as parameters, amounts, time intervals, and the like, are meant to encompass variations from the value relative to the specified value, such as variations of ±10% or less, preferably ±5% or less, more preferably ±1% or less, and even more preferably ±0.1% or less, from the value relative to the specified value, where such variations are appropriate to practice the disclosed invention. It will be understood that values such as those modified by "about" or "approximately" are themselves specifically and preferably disclosed.
[0059] On the other hand, the term "one or more" or "at least one", e.g., one or more members or at least one member of a group of members, is clear in itself, and by way of further example, the term specifically encompasses reference to any one of said members, or any two or more of said members, e.g., any three or more, four or more, five or more, six or more, seven or more, etc. of said members, up to all of said members. In another example, "one or more" or "at least one" may refer to 1, 2, 3, 4, 5, 6, 7, or more.
[0060] The discussion of the background to the invention herein is included to explain the context of the invention, and is not intended as an admission that any of the material referred to was published, known, or common general knowledge in any country as of the priority date of any of the claims.
[0061] Throughout this disclosure, various publications, patents, and published patent specifications are referenced with an identifying citation. All publications cited herein are incorporated by reference in their entirety. In particular, the teachings or sections of such publications that are specifically mentioned in this specification are incorporated by reference.
[0062] Unless otherwise defined, all terms used in the disclosure of the present invention, including technical and scientific terms, have the meanings as commonly understood by those skilled in the art to which the present invention belongs. As further guidance, definitions of terms are included so that the teachings of the present invention can be better understood. When a particular term is defined in relation to a particular aspect of the present invention or a particular embodiment of the present invention, such relation or meaning is meant to apply throughout the specification, i.e., in the context of other aspects or embodiments of the present invention, unless otherwise defined. For example, an embodiment relating to a product can also be applied to the corresponding features of the method and use.
[0063] In the following sections, different aspects or embodiments of the invention are defined in more detail. Each aspect or embodiment so defined can be combined with any other aspect(s) or embodiment(s), unless expressly stated to the contrary. In particular, any feature indicated as being preferred or advantageous can be combined with any other feature or features indicated as being preferred or advantageous.
[0064] References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with that embodiment is included in at least one embodiment of the invention. Thus, the phrases "in one embodiment" or "in an embodiment" appearing in various places throughout this specification do not necessarily all refer to the same embodiment. Furthermore, particular features, structures, or characteristics can be combined in any suitable manner in one or more embodiments, as would be apparent to one of ordinary skill in the art from this disclosure. Furthermore, even if some embodiments described herein include some features but not other features included in other embodiments, as would be understood by one of ordinary skill in the art, combinations of features of different embodiments are meant to be within the scope of the invention and form different embodiments. For example, the appended claims encompass alternative combinations of the claimed embodiments, as would be understood by one of ordinary skill in the art.
[0065] General definition and context of the invention The term "estetrol component" as used throughout the present specification includes substances selected from the group consisting of estetrol, esters of estetrol in which at least one hydrogen atom of the hydroxyl group is replaced by an acyl radical of a hydrocarbon carboxylic acid, sulfonic acid, or sulfamic acid of 1 to 25 carbon atoms, estetrol hydrates, such as estetrol monohydrate, and combinations thereof. When estetrol is mentioned throughout any part of the present specification, it is understood that any estetrol-containing component (i.e., compound) and / or estetrol derivative (e.g., estetrol ester) is also envisaged. More preferably, in the context of the present disclosure, a particularly preferred estetrol component suitable for the dosage units or cosmetic or medical uses and treatment methods described herein is estetrol (including estetrol hydrate). Most preferably, the estetrol component is estetrol monohydrate.
[0066] The term "estetrol" as used herein refers to 1,3,5(10)-estratriene-3,15α,16α,17β-tetrol or 15α-hydroxyestriol, as well as hydrates of estetrol, such as estetrol monohydrate. "Estetrol" or "E4" for short is an estrogenic steroid (PubChemCID:27125) produced by fetal human liver. Estetrol can be described as a 3-hydroxysteroid corresponding to 17β-estradiol with two additional hydroxyl groups substituted at the 15α and 16α positions. Estetrol is known to be an estrogen receptor agonist (Coelingh Bennink et al., Estetrol review: profile and potential clinical applications, Climacteric, 2008). When the estetrol component described herein refers to estetrol, the estetrol can be endogenous estetrol. Alternatively, estetrol may be chemically synthesized, synthesized by the use of (mutant) recombinant enzymes, or any combination thereof. Estetrol is alternatively known in the art as having the molecular formula: 18 H 24 O4, or may also be represented by structural formula (I):
[0067] [ka]
[0068] In a preferred embodiment, estetrol is present or used herein as the monohydrate.
[0069] In some embodiments, the estetrol component can be the sole active ingredient or can be combined with any other cosmetic or pharmaceutical active agent or ingredient known in the art for improving or maintaining the quality and / or appearance of skin, or for preventing or treating skin aging.
[0070] In preferred embodiments, the estetrol component is administered without a progestogen component, however, in some embodiments, for example if the patient still has a uterus, an optional progestogen component can be administered in addition to the estetrol component.
[0071] The terms "progestogen", "progestogen", "gestagen" or "gestogen" and their derivatives "progestogenic compound", as used herein and in the art, refer to any molecule that produces an effect in the subject's body similar to that of the natural female hormone progesterone. Progestogens are considered to be agonists of the progesterone receptor, and their functions have been thoroughly investigated in the art (especially reviewed in Kuhl, Pharmacology of estrogens and progestogens: influence of different routes of administration, Climacteric, 2005). Progestins are a subgroup of progestogens, and this subgroup includes synthetic progestogens. Although the above terms may be used interchangeably in the art, as a general understanding, when progestins are mentioned, they refer to synthetic progestogens.
[0072] Examples of progestins include levonorgestrel, norgestimate, norethisterone, dydrogesterone, drospirenone, 3-β-hydroxydesogestrel, 3-ketodesogestrel, 17-deacetylnorgestimate, 19-norprogesterone, acetoxypregnenolone, allylestrenol, amgestone, chlormadinone, cyproterone, demegestone, desogestrel, dienogest, dihydrogesterone, dimethisterone, ethisterone, ethynodiol diacetate, fluorogestone acetate, gastrinon, gestodene, gestrinone, hydroxymethylprogesterone, hydroxyprogesterone, lynestrenol, mesirogestron, medroxyprogesterone, megestrol, melengestrol, nomegestrol, norethindrone, norethynodrel, norgestrel (d-norgestrel and dl-norgestrel). (including lugestrel), norgestrienone, normethisterone, progesterone, quingestanol, (17α)-17-hydroxy-11-methylene-19-norpregna-4,15-dien-20-yn-3-one, tibolone, trimegestone, algestone-acetophenide, nestrone, promegestone, 17-hydroxyprogesterone ester, 19-nor-17-hydroxyprogesterone, 17α-ethynyltestosterone, ... These include tosterone, 17α-ethynyl-19-nortestosterone, d-17β-acetoxy-13β-ethyl-17α-ethynylgon-4-en-3-one oxime, 6β,7β;15β,16β-dimethylene-3-oxo-17-pregna-4,9(11)-diene-21,17β-carbolactone or tanaproget, and precursors of these compounds which are capable of liberating these progestogens in vivo.
[0073] Drospirenone (abbreviated as DRSP, PubChem CID: 68873) is an example of a progestin that has become increasingly widely used in combined oral contraceptives (COCs) due to its anti-mineralocorticoid and anti-androgenic effects combined with low overall off-target activity. Drospirenone-containing COCs are generally referred to as fourth generation COCs. Non-limiting examples of commercially available COCs containing drospirenone are known as "Yaz™" and "Yasmin™". An example of a progestogen-only drospirenone oral contraceptive is "Slynd™" (also commercially available). Additionally, HRT compositions containing estrogens such as estradiol and drospirenone are available, such as "Angeliq™". Drospirenone is alternatively known in the art by its molecular formula C 24 H 30 O3, or may be represented by structural formula (II):
[0074] [ka]
[0075] It will be appreciated that when the term "drospirenone" is used herein, any drospirenone derivative is also contemplated.
[0076] By way of example and not limitation, other progestogens or progestins that have been used in COCs include norethisterone, norethindrone, levonorgestrel (LNG), norgestrel, gestodene, desogestrel, norgestimate, cyproterone acetate, dienogest, and chlormadinone.
[0077] In the context of the present invention, other components can be used in combination with estetrol component for administration to women with uterus.Selective estrogen receptor modulator (SERM) defines a category of such compounds that is expected to be useful complement to estetrol component in the method of the present invention.The preferred SERM for use in the context of the present invention is bazedoxifene.
[0078] In the methods and compositions further described herein, when reference is made to a "progestogen component," it should be understood that such reference includes SERMs, particularly bazedoxifene.
[0079] The term "effective amount" refers to the amount necessary to obtain a physiological effect, which can be achieved by a single administration or by repeated administrations.
[0080] A preferred subject is a female human subject.
[0081] In certain embodiments, the subject is a menopausal, peri-menopausal, and / or post-menopausal female subject.In certain embodiments, the subject is a menopausal, peri-menopausal, or post-menopausal subject with an estradiol level of less than 100 pg / ml, preferably less than 50 pg / ml, preferably less than 30 pg / ml, more preferably less than 20 pg / ml, more preferably less than 20 pg / ml, and most preferably less than 10 pg / ml.In alternative embodiments, the subject is a menopausal, peri-menopausal, or post-menopausal subject characterized by a follicle stimulating hormone concentration of at least 20 milli-international units per milliliter (mIU / ml), preferably at least 25 mIU / ml, more preferably at least 30 mIU / ml, more preferably at least 35 mIU / ml, and most preferably at least 40 mIU / ml.
[0082] "Menopausal subject", which is used interchangeably in the art with "postmenopausal subject" or "menopausal subject", refers to a female subject who has not had menstrual bleeding for one year, accompanied by a decrease or cessation of hormone (e.g. estradiol) production by the ovaries. In other words, "menopause" can be described as a biological state characterized by the impairment or cessation of the primary function of the ovaries. Menopause may be accompanied by a wide range of clinical symptoms of varying severity, including, but not limited to, vascular dysfunction, vaginal dryness, mood changes, sleep disorders, urinary incontinence, cognitive changes, physical complaints, and sexual dysfunction. Methods for diagnosing menopause have been described in the art and are therefore known to those skilled in the art (Nelson, Menopause, Lancet, 2008).
[0083] "Perimenopause" refers to the period of life that begins approximately 3-4 years before menopause and ends one year after the last menstrual period, and is characterized by persistent irregular menstrual cycles, extreme fluctuations in hormone levels, frequent anovulation, and the appearance of vasomotor symptoms (Harlow et al., Executive summary of the Stages of Reproductive Aging Workshop+10: addressing the unfinished agenda of staging reproductive aging, Menopause, 2012). The term "postmenopause" or "post-menopausal" refers to a female subject characterized by a permanent cessation of menstrual periods. This permanent cessation is determined retrospectively after 12 months of observation of amenorrhea without any other obvious pathological or physiological cause. The term "postmenopause" also includes menopause as a result of premature ovarian failure, surgery (e.g., oophorectomy), chemotherapy or radiation therapy for cancer, and certain diseases (e.g., infection or hypothyroidism).
[0084] Preferred subject is elderly subject, more preferably elderly female subject.Those skilled in the art will recognize that elderly subject is subject whose age is above the average and / or median age of general population.For example, elderly subject described herein can be at least 40 years old, at least 45 years old, at least 50 years old, at least 55 years old, at least 60 years old, or at least 65 years old.
[0085] Those skilled in the art understand that human skin can generally be considered to include three distinct layers: the epidermis, the dermis, and the subcutaneous tissue. The epidermis is the top layer of the skin, which is composed primarily of keratinocytes, i.e., epidermal cells that proliferate and differentiate to eventually produce the stratum corneum (the outermost layer of dead skin cells). The epidermis forms a barrier against environmental pathogens such as bacteria, regulates the amount of water released from the body, and plays a major role in wound healing. The second skin layer, the dermis (alternatively the "dermal layer" or "cutaneous connective tissue"), is located between the subcutaneous tissue and the epidermis and is composed primarily of (mesenchymal) fibroblasts. The dermis is tightly connected to the epidermis by a basement membrane (i.e., a type of sheet-like extracellular matrix). Furthermore, the dermis is much thicker than the epidermis, and fibroblasts within the dermis produce extracellular matrix (collagen, glycosaminoglycans including hyaluronic acid, elastic fibers, etc.). The main roles of the dermis are to maintain the thickness and elasticity of the skin, to keep the skin moist (due to the water-retaining properties of glycosaminoglycans, including hyaluronic acid), and to effect wound healing, i.e., by reforming and remodeling damaged extracellular matrix. The deepest layer of the skin is commonly referred to as the "subcutaneous tissue" and is noted in the art as synonymous with terms such as "subcutaneous tissue", "subcutis", and "superficial fascia".
[0086] The term "skin aging" as used herein corresponds to all kinds of effects of aging on the skin, i.e. all dermatological changes resulting from global hypoestrogenism or menopause, in particular the so-called menopausal skin aging (menopausal skin). Such changes include, for example, changes at the cellular level (keratinocytes, fibroblasts, melanocytes, sebocytes, etc.) or at the level of the composition of the extracellular matrix (elastin, fibrillin, collagen, etc.), which are inter alia aggravated by a deterioration in skin health, an increase in skin fragility mediated by a decrease in skin thickness (dermis and / or epidermis), a decrease in skin collagen content, a decrease in skin moisturization, a decrease in skin elasticity, an increase in skin water loss (skin dryness), a decrease in keratinocyte function, a decrease in skin fibroblast function, a decrease in skin barrier function, an increase in oxidative stress. These may result in increased sebum secretion, uneven skin pigmentation, changes in skin extensibility, changes in hysteresis, decreased skin brightness, decreased epidermal barrier lipids, decreased sebum secretion, decreased skin firmness, development of facial wrinkles (including, but not limited to, frown lines, lateral canthal wrinkles, and forehead wrinkles), impaired wound healing, skin breakouts (acne), increased inflammation and associated skin irritation or pruritus, and the onset or worsening of psoriasis associated with or exacerbated by menopausal hormone deregulation, such as estrogen deficiency (e.g., hypoestrogenism) associated with menopause.
[0087] The term "skin health" encompasses the overall health of the skin, including skin texture, skin quality and skin appearance. However, skin texture and skin quality and skin appearance are understood by those skilled in the art to be distinct characteristics (i.e. properties) of skin. Skin texture refers only to the texture pattern of the skin surface, i.e., an indication of how the skin feels to the touch (e.g. smooth, rough, bumpy). In contrast, skin quality and skin appearance refer to attributes that are further described herein. In particular, skin appearance refers to the visible appearance of the skin, which must be considered independently of the skin's feel to the touch.
[0088] The term "skin fragility" as used in this disclosure, or the related expression "fragile skin", should be construed as any skin that is less resistant to irritation when compared to normal skin (e.g., skin of a healthy adult aged 18-45 years). Skin fragility is typically increased in older subjects, as well as in perimenopausal, postmenopausal, and menopausal women. Hallmarks of skin fragility include, but are not limited to, the appearance of atrophic skin, senile purpura, white pseudoscars, and reduced overall epidermal and dermal thickness compared to normal skin. The occurrence of increased skin fragility mediated by aging is known to those skilled in the art and has been widely documented in the art (e.g., Dyer and Miller, Chronic Skin Fragility of Aging, J Clin AesthetDermatol, 2018).
[0089] The expression "skin inflammation" or "skin inflammation" used herein should be interpreted according to the meaning generally accepted in the art, and therefore refers to any localized skin immune reaction.In the context of the present invention, the cause of skin inflammation is not particularly limited, and includes, for example, pathogens, immune system dysfunction, allergic reaction, and wound.Therefore, skin inflammation can be considered as the result of cell-cell interaction in the skin of a subject, with immune cells remaining the most important cell type.
[0090] "Sebum" as used herein refers to the oily and / or waxy substance produced in the sebaceous gland by sebocytes, which are highly specialized epithelial cells that secrete sebum by holocrine secretion. Sebum is a composition that includes triglycerides, wax esters, squalene, and free fatty acids, and forms an integral component of the epidermal barrier and the skin's immune system. Sebaceous glands develop from the same tissue that gives rise to the epidermis and can be classified into sebaceous glands that are connected to hair follicles and those that exist independently.
[0091] The inventors have unexpectedly found that estetrol has a beneficial effect on keratinocyte proliferation and function.
[0092] The term "keratinocyte" includes a type of cell in the epidermis, which accounts for about 90% of the cells in the outermost layer of the skin. Keratinocytes proliferate and differentiate, eventually generating the stratum corneum, the outermost layer of the skin. The main roles of keratinocytes include forming a skin barrier, ensuring moisture retention through the water-retaining capacity of the stratum corneum, and wound healing by closing the epidermal barrier. The term "increased skin keratinocyte function" is intended to include both increased proliferation of keratinocytes in the epidermis and increased, improved or restored function of keratinocytes in the skin. The function provides, but is not limited to, skin thickness and moisture retention, which provides sufficient skin barrier and ensures proper wound healing.
[0093] Keratinocytes also play a role in oxidation and inflammation. Increased ROS production (especially produced by keratinocytes) and oxidative stress can cause DNA, protein and lipid damage, leading to premature skin aging. Chronic low-grade inflammation damages the skin, especially by increasing the expression of pro-inflammatory cytokines by keratinocytes, which leads to deleterious changes and premature skin aging and hair loss.
[0094] Furthermore, skin pigmentation is influenced by keratinocytes and melanocytes whose main function is the production of melanin pigment. Melanocytes are surrounded by keratinocytes, which transfer their melanin pigment to keratinocytes. Due to the close interaction and communication between melanocytes and keratinocytes, a single melanocyte can be surrounded by keratinocytes, thereby influencing the keratinocytes, for example by estetrol, and thus influencing the melanocytes and thus pigmentation. The term "melanin" as used in this disclosure refers to a group of natural pigments produced by melanocytes localized in the epidermis. Various types of melanin have been described in the art (e.g., Wei et al., Unravelling the structure and function of Melaninthrough synthesis, J Am Chem Soc, 2021). "Melanogenesis" is commonly used in the art and refers to the process of melanin production. Melanogenesis, for example, is upregulated when skin is exposed to ultraviolet radiation, resulting in a darkening of skin tone.
[0095] Keratinocytes are also a key cell type for promoting wound healing, responsible not only for wound closure and re-epithelialization, but also for regulating inflammation in the wound adjacent to immune cells. An imbalance in keratinocyte function can lead to unbalanced inflammation.
[0096] Keratinocytes also play an active role in the initiation and maintenance of psoriatic skin inflammation by secreting chemokines, cytokines, and antimicrobial peptides, which leads to further chemoattraction and activation of immune cells in the skin, amplifying the inflammatory process (Nestle et al., Psoriasis. N Engl J Med 2009; 361: 496-509). Keratinocytes also act as a source of reactive oxygen species (ROS) by delivering hydrogen peroxide to melanocytes (Pelle et al., Journal ofInvestigative Dermatology; Volume 124, Issue 4, April 2005, Pages 793-797). Therefore, keratinocyte dysfunction is expected to cause or at least aggravate psoriasis.
[0097] The term "reactive oxygen species" (commonly abbreviated as "ROS") is a collective term for molecules formed from oxygen (O2). Examples for understanding are peroxides, superoxide, hydroxyl radical, singlet oxygen, and alpha oxygen. Reactive oxygen species are produced, among others, in fibroblasts and keratinocytes. While both the dermis and epidermis can protect the skin from oxidation, the epidermis contains the highest concentration of antioxidants.
[0098] Furthermore, the inventors have found that estetrol also favourably influences the proliferation and function of fibroblasts in the skin, and more particularly in the dermis of the skin.
[0099] Dermal fibroblasts or dermal fibroblasts are the major cell type present in the skin connective tissue (dermis). Fibroblasts produce extracellular matrix including collagen, glycosaminoglycans including hyaluronic acid, and elastic fibers. Fibroblast functions affect skin thickness and elasticity, skin hydration via the water-holding capacity of glycosaminoglycans including hyaluronic acid, and wound healing via reformation and remodeling of damaged extracellular matrix. Fibroblasts interact with epidermal cells during hair development and in interfollicular skin. Thus, fibroblasts play an essential role during skin wound healing and are crucial for maintaining good skin health as mentioned above. With regard to elasticity, it is believed that fibroblasts produce dermal elastic fibers such as tropoelastin and fibrillin-1.
[0100] Fibroblasts play a role in skin moisturization through the production of glycosaminoglycans and hyaluronic acid (HA) by hyaluronan synthase (HAS), which results in increased dermal moisture absorption. Altered fibroblast function can lead to reduced matrix deposition and impaired skin remodeling due to a change in the balance between extracellular matrix (ECM) synthesis and degradation, accompanied by an increase in MMP expression, specifically MMP-2 and MMP-9.
[0101] "Matrix metalloproteinases", "matrix metallopeptidases", "matrixins" or "MMPs" for short are enzymes that can degrade extracellular matrix proteins. In skin, MMPs degrade the extracellular matrix in the dermis, including collagen, fibronectin, elastin and glycosaminoglycans. The expression of MMPs has been reported in the art to be upregulated upon exposure to UV radiation, with both UVA (320 nm to 400 nm) and UVB (290 nm to 320 nm) radiation being able to achieve this effect (Pittayapruek et al., Role of Matrix Metalloproteinases in Photoagingand Photocarcinogenesis, Int J Mol Sci, 2016).
[0102] Eruptive xanthomas is a skin condition caused by excessive blood lipids. It can occur in subjects with poorly controlled diabetes, with very high triglycerides and high cholesterol. Some drugs, such as isotretinoin, estrogen and cyclosporine, can increase triglyceride levels. Unlike other estrogens, E4 has been documented to have little effect on lipid and triglyceride levels in humans. Use of E4 has only limited effect on lipid / triglyceride levels, and therefore may have less effect on lipid-dependent skin conditions when compared to other skin treatment hormone therapies.
[0103] Anti-aging therapy for the skin, improving skin health, reducing skin fragility, improving or maintaining skin quality and / or skin appearance, reducing or preventing skin porosis In one aspect, the present invention provides a composition comprising an estetrol component for use in preventing or treating skin aging as defined elsewhere herein. In another way, the present invention contemplates the use of a composition comprising an estetrol component for preventing or treating skin aging, including improving overall skin health and reducing skin fragility. In yet another way, the present invention contemplates the use of an estetrol component (or a composition comprising an estetrol component) for the manufacture of a medicament for preventing or treating skin aging, improving overall skin health, and reducing skin fragility. Finally, the present invention further provides a method of treatment for preventing or reducing skin aging, improving overall skin health, and reducing skin fragility, comprising administering a composition comprising systemic administration of the estetrol component to a subject. Without wishing to be bound by any theory, the positive effects of the estetrol component may be obtained by reducing inflammation, preventing or reducing the production of new matrix by aged or aging cells, preventing or reducing extracellular matrix turnover, inhibiting oxidative stress in aged or aging cells, and improving the overall function of aged or aging epidermal cells.
[0104] One particular embodiment relates to improving and / or maintaining skin quality and / or skin appearance, optionally in the context of skin aging, and optionally in the context of skin porosis or psoriasis. Those skilled in the art understand that "skin quality" should be evaluated as a collection of visual, mechanical, and topographical properties of the skin (Humphrey et al., Dermatol Surg, 2021). Visible attributes are purely visible and are evaluated by the reflection of light on the skin, even after complete removal and smoothing of topographical imperfections of the skin. Topographical attributes are perceived by touch and seen by topographical images. Mechanical attributes relate to the movement of the skin and can be measured by physical manipulation or deformation of the skin. Optionally, the dosage units for use, uses, or methods described herein can improve or maintain each of the above characteristics. Alternatively, the dosage units for use, uses, or methods described herein can improve at least one or at least two of the characteristics.
[0105] The concepts of skin quality and skin appearance may alternatively be reported in the art by deviations from ideal skin. Thus, the dosage units, uses, or methods for use described herein may address the following skin problems: uneven pigmentation (i.e., changes in melanin), redness (i.e., erythema or visible hemoglobin), dullness / sallowness (i.e., lack of radiance; yellowish or grayish undertones), brightness (i.e., the skin's ability to "shine" or reflect light), oiliness / shininess (i.e., excess sebum on the skin's surface), dryness (i.e., lack of moisture; dehydration), fine lines (i.e., light wrinkles), pronounced wrinkles (slight wrinkles), ... The present invention may be directed to (i.e., to improve) one or more attributes of skin quality and / or skin appearance selected from the group consisting of: wrinkles, pores (i.e., surface landmarks of the pilosebaceous unit), crepiness (i.e., fine cigarette paper-like wrinkles in the skin), moisturization (i.e., water content; wetness), laxity (i.e., loose skin), elasticity / softness (i.e., resilience to palpation), firmness (i.e., ability to stretch), thickness (i.e., density of the epidermis and dermis), and roughness. Non-limiting methods and techniques for measuring and quantifying each of these attributes are well documented throughout the art and are therefore known to those of skill in the art (e.g., Humphrey et al., Dermatol Surg, 2021).
[0106] In addition to the above, the compositions described herein are particularly effective for improving collagen density, the appearance of wrinkles, wrinkle depth, or any combination thereof.
[0107] The specific subject envisaged herein may be a subject diagnosed with dermatoporosis, considered to have dermatoporosis, or predicted to develop dermatoporosis. "Dermatoporosis" and its clinical features are described in the art and known to those skilled in the art (e.g., Wollina et al., Open Access Maced J Med Sci, 2019). Dermatoporosis encompasses all aspects of chronic skin fragility syndrome, thus encompassing a functional reduction that leads to the breakdown of the protective mechanisms of human skin, and mainly affects elderly subjects.
[0108] Dermatoporosis is characterized by reduced expression of collagen I, reduced expression of collagen III, reduced expression of collagen IV, increased expression of matrix metalloproteinase 1, increased expression of matrix metalloproteinase 2, increased expression of matrix metalloproteinase 3, reduced expression of matrix metalloprotein I, reduced elastic tissue, defective collagen synthesis by fibroblasts, reduced hyaluronic acid, or any combination thereof. Thus, in the context of the present invention, a subject that has not been diagnosed with dermatoporosis, optionally even an elderly subject, may be considered to have dermatoporosis or may be predicted to develop dermatoporosis if it shows reduced expression of collagen I, reduced expression of collagen III, reduced expression of collagen IV, increased expression of matrix metalloproteinase 1, increased expression of matrix metalloproteinase 2, increased expression of matrix metalloproteinase 3, reduced expression of matrix metalloprotein I, reduced elastic tissue, defective collagen synthesis by fibroblasts, reduced hyaluronic acid, or any combination thereof.
[0109] Subjects affected by dermatoporosis are generally classified into four clearly distinguishable stages, each representing a specific clinical picture (Saurat et al., J EurAcad Dermatol Venereol, 2017).
[0110] [Table 1]
[0111] Thus, the dosage units for use, uses and methods described herein may be intended for and therefore relate to the treatment and / or prevention of any stage of dermatoporosis, preferably selected from the group consisting of stage I, stage IIa, stage IIb, stage IIIa, stage IIIb, stage IV, or any combination thereof. Optionally, the stage of dermatoporosis may be selected from stage I, stage IIa, and stage IIb. Alternatively, the stage of dermatoporosis may be selected from stage IIIa, stage IIIb, and stage IV.
[0112] Lowering inflammatory markers The inventors have unexpectedly found that administration of the estetrol component to a subject reduces inflammatory markers typically released and / or elevated in or by dysfunctional skin tissue, aging skin tissue, or skin of suboptimal quality and / or appearance. In other words, a general reduction in (the degree of) inflammation can be observed. By way of example and not limitation, an inflammatory marker that is significantly reduced by an effective amount of the estetrol component as described herein is interleukin-6 (IL-6). Interleukin-6 has been extensively studied and its role in inflammation is well documented (see, for example, Kaur et al., Bioorg Med Chem, 2020). More specifically, administration of the estetrol component to a subject reduces the release of interleukin-6 when compared to a control condition in which a different estrogen (i.e., not estetrol) is administered to the subject. By way of example and not limitation, suitable estrogens that can be administered to provide a control condition include estrone (E1), estradiol (E2), estriol (E3), and ethinylestradiol (EE). The dosage units, uses, and methods described herein each have the effect of reducing the release of interleukin-6 by at least 5%, preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 50%, or even more than 50%, when compared to a control condition as described above.
[0113] Treatment, therapy, administration The term "treatment" or "treating" is understood to refer to both therapeutic treatment of symptoms, diseases or conditions that have already developed and (clinically) manifested, and preventative or preventive measures, where the purpose of treatment is to prevent, reduce or reduce the likelihood of undesired suffering, for example, to prevent the onset, progression and development of symptoms, clinical (conditions) or diseases associated with skin aging.Accordingly, a further aspect of the present invention relates to an effective amount of estetrol component used to prevent skin aging in a subject, preferably a menopausal subject.Beneficial or desired clinical results include (but are not limited to) alleviation of one or more symptoms, improvement of one or more biological markers, disappearance of the spread of disease, stabilization (i.e., not worsening) of disease state, delay or slowing of disease progression, improvement or alleviation of disease state, etc.
[0114] "Prevention" or "preventing" as used in the context of the present invention refers to the avoidance of the manifestation of a disease state in a subject, i.e., the establishment of a preventative or preventative measure. Prophylactic treatment refers to treatment aimed at keeping the subject's body or its elements from exhibiting (the worsening of) symptoms of undesirable physiological changes.
[0115] Terms such as "therapeutic treatment" or "therapy" as used herein refer to treatments aimed at changing a subject's body or a part of a subject's body from an undesirable physiological condition, disease or disorder caused by aging to a desirable condition, e.g., a milder condition (e.g., improvement or mitigation) or even its normal health condition (e.g., restoring the subject's health, physical integrity and physical health), maintaining it in the undesirable physiological condition (i.e., not worsening) (e.g., stabilizing), or slowing down the progression to a more severe or worse condition compared to the undesirable physiological change or disorder. Measurable relief includes any statistically significant reduction in a measurable marker or symptom. Statistically significant as used herein refers to a p-value of less than 0.05, which is a commonly accepted cutoff value for statistical analysis as understood by those skilled in the art. "Treatment" encompasses both curative treatments and treatments that reduce symptoms and / or slow progression and / or stabilize a condition or disease.
[0116] Those skilled in the art recognize that to achieve an effective therapeutic treatment, a therapeutically effective dose must be administered to the subject. Thus, in the context of the present disclosure, "effective amount" refers to the amount necessary to obtain a physiological effect. The physiological effect may be obtained by a single administration or multiple administrations. "Therapeutically effective amount" or "therapeutically effective dose" refers to an amount of the estetrol component that, when administered, results in a clinically beneficial response with respect to the treatment of a subject suffering from skin aging. Similarly, "preventively effective amount" or "preventively effective dose" refers to an amount of the estetrol component that inhibits or delays the onset of (clinical) manifestations of skin aging. Those skilled in the art recognize that terms such as "amount," "quantity," and "level" are synonymous and have well-defined meanings in the art, and understand that they can refer to an absolute quantification of the estetrol component that is considered an effective amount, particularly for the applications described herein, or a relative quantification of the estetrol component, such as, for example, the concentration of the estetrol component based on the subject's body weight. A suitable value or range of values can be obtained from one subject or a group of subjects (ie, at least two subjects).
[0117] It is emphasized that any value and range of estetrol component disclosed herein is suitable for different medical indications or purposes, but those skilled in the art recognize that a particular individual may experience further improved benefits from estetrol component treatment by further optimizing the optimal dosage of the component by considering a wide range of parameters, including but not limited to the nature and extent of the condition or disease to be treated, the subject's sex, the subject's age, weight, other medical indications, nutritional status, method of administration, metabolic status, interference or influence or effect of other pharmacoactive ingredients, etc. Furthermore, each individual may have a particular inherent reactivity to the estetrol component used.
[0118] The terms "subject," "patient," "individual," and the like may be used interchangeably herein and refer to a human subject, preferably a female subject who is in the menopausal or perimenopausal stage of her life.
[0119] Cosmetic methods for preventing or reducing skin aging are also envisaged, comprising the systemic administration of a composition comprising an estetrol component. In other words, the present invention also envisages the cosmetic use of a composition comprising an estetrol component for preventing or reducing skin aging. Those skilled in the art will understand that "cosmetic use" refers to "non-medical, non-therapeutic use", and therefore to use that is not intended to alleviate, prevent or treat clinical pathology.
[0120] The therapy or cosmetic therapy of the present invention typically employs continuous administration of the estetrol component for a period of at least 10 days, preferably at least 20 days.
[0121] The estetrol component is administered in a daily dosage of about 10 mg to about 25 mg of the estetrol component, preferably estetrol, more preferably estetrol monohydrate.
[0122] In certain embodiments, the estetrol component is administered in a daily dosage of about 14 mg to about 21 mg.
[0123] In another specific embodiment, the estetrol component is administered in a daily dosage of about 14 mg to about 16 mg, or about 19 mg to about 21 mg.
[0124] In one embodiment, the therapeutic or cosmetic regimen of the present invention is administered to a non-hysterectomized patient. In a particular embodiment, the therapeutic or cosmetic regimen of the present invention comprises daily administration of about 15 mg or about 20 mg of an estetrol component, preferably to a non-hysterectomized patient.
[0125] When the therapeutic or cosmetic treatment of the present invention is administered to a patient who has undergone a hysterectomy, the estetrol component is preferably administered without a progestogen component, or even as the only active ingredient.
[0126] When the therapeutic or cosmetic treatment of the present invention is administered to a non-hysterectomized patient, the estetrol component can be administered as the sole active ingredient or together with an optional progestogen component. The optional progestogen component can be administered continuously (i.e., daily in addition to the estetrol component) or sequentially (sequentially meaning, for example, administration of the progestogen component for 10 to 14 days every month, or 14 days every three months).
[0127] The term "continuous" / "sequentially" as used herein means that the components are administered at relatively regular intervals without any (therapeutic) significant interruption. Of course, minor interruptions that do not affect the overall effectiveness of the method of the present invention may occur, and in fact, such deviations are also encompassed by the present invention. In a preferred embodiment, more mathematically, a dosing regimen is considered continuous if the longest interval between two consecutive administrations is 3.5 times or less than the average interval. Even more preferably, the longest interval is 2.5 times or less than the average interval, and most preferably 1.5 times or less.
[0128] In one embodiment, the optional progestogen component is administered parenterally, for example, using an intrauterine device (IUD). In one embodiment, the IUD delivers the progestogen component levonorgestrel. In one such embodiment, the IUD is a Mirena™ IUD or a Levosert™ IUD.
[0129] Thus, one skilled in the art will appreciate that the estetrol component can be administered with any other cosmetically or pharma- ceutical active agent known in the art for reducing or preventing skin aging.
[0130] In one embodiment, the therapeutic or cosmetic treatment of the present invention uses oral, sublingual, buccal, or labial administration of the estetrol component. The latter three administration methods offer the advantage that the estetrol component does not have to pass through the digestive system, avoiding first-pass liver exposure. Furthermore, these administration methods provide a rapid onset of action.
[0131] The term "sublingual" as used herein refers to a pharmacological route of administration that allows the estetrol component to diffuse through the sublingual tissue into the blood.
[0132] The term "oral cavity" as used herein refers to a pharmacological route of administration in which the estetrol component diffuses into the blood through the tissues of the oral cavity vestibule, i.e., the inner region of the mouth between the back of the cheek (buccal mucosa) and the teeth / gums. The term "lips" as used herein refers to a pharmacological route of administration in which the estetrol component is placed between the lips and the gums. In the therapeutic or cosmetic method of the present invention, the estetrol component and the progestogen component can be administered in separate dosage units. However, it is also possible, and indeed very convenient, to combine these two components into a single dosage unit.
[0133] In the therapeutic or cosmetic method of the present invention, the combination of the progestogen component and the estetrol component is suitably administered for at least 10 consecutive days.
[0134] The present invention can be suitably simplified to be implemented in the form of various administration methods known to those skilled in the art, among which is the use of a single-phase preparation comprising a dosage unit containing a fixed amount of the estetrol component and an optional progestogen component.
[0135] In embodiments of the invention in which sequential administration of the progestogen components is selected, it may be possible and convenient to combine the two components into a single dosage unit on the days they are administered.
[0136] In another embodiment of the invention, the subject is a postmenopausal subject.
[0137] In certain embodiments, the compositions described herein intended for systemic administration are used in conjunction with cosmetic compositions intended for local (i.e., transdermal) administration that do not contain estrogen, and preferably the cosmetic composition does not contain hormones.
[0138] composition The estetrol component of the present invention includes substances selected from the group consisting of estetrol, esters of estetrol in which at least one hydrogen atom of the hydroxyl group is replaced by an acyl radical of a hydrocarbon carboxylic acid, sulfonic acid or sulfamic acid of 1 to 25 carbon atoms, and combinations thereof. More preferably, the estetrol component is estetrol (including estetrol hydrate). Most preferably, the estetrol component contained in the dosage unit is estetrol monohydrate.
[0139] The estetrol component of the present invention is used in a daily dosage equivalent to about 10 mg to about 25 mg of estetrol monohydrate. In other words, if the estetrol component is not estetrol monohydrate itself, the daily dosage of the estetrol component is adjusted to obtain a pharmaceutical effect equivalent to a daily dosage of about 10 mg to about 25 mg of estetrol monohydrate, for example, about 14 mg to 16 mg of estetrol, preferably estetrol monohydrate, or about 19 mg to 21 mg of estetrol, preferably estetrol monohydrate.
[0140] In a particularly preferred embodiment of the invention, the pharmaceutical composition according to the invention is designed for daily administration, ie it represents a daily dosage unit.
[0141] For oral administration, the oral dosage units (used interchangeably with the term "dosage form") of the present invention are preferably solid or semi-solid dosage units, such as tablets, capsules, cachets, pellets, pills, powders and granules. The term "solid or semi-solid dosage units" also includes capsules containing a liquid, such as an oil, in which the estetrol component of the present invention and / or the optional progestogen component is dissolved or dispersed. Tablets and equivalent solid or semi-solid dosage units can suitably contain materials such as binders (e.g., hydroxypropylmethylcellulose, polyvinylpyrrolidone, other cellulose-based materials and starches), diluents (e.g., lactose and other sugars, starch, dicalcium phosphate and cellulose-based materials), disintegrants (e.g., starch polymers and cellulose-based materials), and lubricants (e.g., stearates and talc). These tablets and equivalent solid dosage units can be prepared, for example, by wet granulation using aqueous or organic solutions, and direct compression.
[0142] For sublingual, buccal or labial administration, the pharmaceutical composition according to the invention is preferably an orodispersible dosage unit.
[0143] The term "orodispersible dosage unit" as used herein refers to a dosage unit designed to disintegrate rapidly in the oral cavity upon contact with saliva, dispersing the estetrol component in the saliva so that it can be absorbed through the oral mucosa.
[0144] If the dosage unit is an orodispersible dosage unit, the release rate of the estetrol component from the dosage unit shall be determined in accordance with Ph. Eur. 2.9.1 ("Disintegration of tablets and capsules") and USP <701> The disintegration time can be suitably determined using, for example, a disintegration test using water as the disintegration medium in accordance with the "Disintegration Test" set forth in the "Applied Pharmacopoeia and Compositional Methods" ("Applied Pharmacopoeia and Compositional Methods"). The orodispersible solid dosage units of the present invention, when subjected to said disintegration test, typically disintegrate in less than 5 minutes, more preferably in less than 2 minutes, even more preferably in less than 1.5 minutes, even more preferably in less than 1 minute, even more preferably in less than 45 seconds and most preferably in less than 30 seconds.
[0145] In one embodiment, the dosage unit contains an estetrol component but no progestogen component.
[0146] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and a progestogen component.
[0147] Preferably, the progestogen component is selected from the group consisting of progesterone, drospirenone, dydrogesterone, precursors of these progestogens, and mixtures thereof.
[0148] In one embodiment, the present invention provides a combination composition comprising an estetrol component together with progesterone.
[0149] In one embodiment, the present invention provides a combination composition comprising an estetrol component together with drospirenone.
[0150] In one embodiment, the present invention provides a combination composition comprising an estetrol component together with dydrogesterone.
[0151] The estetrol and progestogen components may be present in separate oral dosage units or may be combined in the same oral dosage unit.
[0152] When the progestogen component of the present invention is drospirenone, it is preferably used in a daily dosage of 0.25 mg to 10 mg, even more preferably about 0.25 mg to about 4 mg, for example about 1 mg to 4 mg, about 1 mg to 3 mg, or about 2.5 mg to 3.5 mg, preferably about 3 mg.
[0153] When the progestogen component of the present invention is dydrogesterone, it is preferably used in a daily dosage of about 5 mg to about 10 mg, more preferably in a daily dosage of about 5 mg.
[0154] When the progestogen component of the present invention is progesterone, it is preferably used in a daily dosage of 50 mg to 200 mg. In one embodiment, progesterone is used in a daily dosage of 50 mg to 100 mg when it is used continuously. In another embodiment, progesterone is used in a daily dosage of 100 mg to 200 mg when it is used sequentially, for example when it is administered for about 14 days each month.
[0155] When using different progestogen components, the daily dosage is adjusted to obtain the same pharmacological effect as a dose of 50 mg to 200 mg of progesterone.
[0156] In a preferred embodiment of the invention, the composition combines the estetrol component and the optional progestogen component in a single dosage unit, preferably a daily dosage unit. In a more preferred embodiment of the invention, the combined daily dosage unit is an oral combined daily dosage unit.
[0157] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and progesterone.
[0158] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and drospirenone.
[0159] In one embodiment, the present invention provides an oral combination daily dosage unit comprising an estetrol component and dydrogesterone.
[0160] In a preferred embodiment of the invention, an oral combination daily dosage unit is provided that combines estetrol in a daily dosage of about 20 mg with progesterone in a daily dosage of about 100 mg.
[0161] In a preferred embodiment, an oral combination daily dosage unit is provided comprising a daily dosage of 14 mg to 16 mg of estetrol or 19 mg to 21 mg of estetrol, preferably estetrol monohydrate, in combination with about 2.5 mg to 3.5 mg of drospirenone.
[0162] In another embodiment of the invention, the estetrol component is administered to a patient who still has a uterus in combination with a selective estrogen receptor modulator (SERM), particularly bazedoxifene. Preferably, bazedoxifene is administered in a daily dosage of about 10 mg to 50 mg. More preferably, bazedoxifene is administered in a daily dosage of about 20 mg.
[0163] In one embodiment, the present invention provides a therapy that omits the progestogen component.
[0164] The meaning of the terms "modulating the average level" or "modulating the level" or "reducing the level" or "increasing the level" as used herein should be seen as encompassing modulating, decreasing, or increasing the protein and / or mRNA expression level of the referenced substance, respectively, when compared to the reference average level in a subject having a particular condition. Protein levels in a subject can be analyzed using standard techniques, such as, for example, ELISA on a sample from the subject. mRNA expression levels in a subject can be analyzed using standard techniques, such as, for example, quantitative RT-PCR (Q-PCR) on a sample from the subject. In another embodiment, modulating includes increasing the protein or expression level.
[0165] In certain preferred embodiments, the estetrol component is contained in solid dosage units, preferably each solid dosage unit contains about 10 mg to 25 mg, for example about 14 mg to 21 mg, or about 14 mg to 16 mg, or about 19 mg to 21 mg, or about 15 mg, or about 20 mg of the estetrol component. In more preferred embodiments, the estetrol component is contained in a tablet, caplet, or capsule, most preferably a tablet. In further embodiments, the solid dosage unit is formulated to correspond to a daily solid dosage unit. In yet further embodiments, the solid dosage unit is an oral dosage unit (i.e., a dosage unit intended to be swallowed by a subject). Thus, in certain embodiments, the medical use or method of treatment comprises daily administration of a solid dosage unit comprising an effective amount of estetrol. In certain embodiments, the effective amount of the estetrol component is contained in a single dosage unit further comprising one or more pharma- ceutical active ingredients, which may be progestogens as defined elsewhere herein, or which may be additional cosmetic or (pharmaceutical) active ingredients for the prevention or treatment of skin aging.
[0166] In alternative embodiments, the solid dosage unit is suitable for sublingual, buccal, and / or labial administration. In such embodiments, the solid dosage unit can rapidly release the estetrol component when contacted with an aqueous solvent such as saliva. Thus, in these embodiments, the solid dosage unit is an orodispersible dosage unit that releases at least about 50%, preferably at least about 60%, more preferably at least about 70%, more preferably at least about 80%, and most preferably about 80% of the estetrol component within about 5 minutes, preferably within about 3 minutes, more preferably within about 2.5 minutes, more preferably within about 90 seconds, and most preferably within about 90 seconds. The term "orodispersible dosage unit" as used herein refers to a dosage unit designed to rapidly disintegrate in the oral cavity when contacted with saliva, dispersing the estetrol component in the saliva so that it can be absorbed through the oral mucosa. Methods for determining the release rate of the estetrol component from a dosage unit are known to those skilled in the art. Standardized tests that are generally accepted in the field include Ph. Eur. 2.9.1 ("Disintegration of tablets and capsules") and USP <701> ("Disintegration") tests, for example but not limited to, using water as the disintegration medium.
[0167] In certain embodiments, the estetrol component is included in an immediate release dosage unit or composition. In alternative embodiments, the estetrol component is included in a delayed release, sustained release, or controlled release dosage unit or composition. The terms "immediate release", "delayed release", and "sustained release" or "controlled release" are clear to those skilled in the art and describe the release profile of a pharmaceutical composition. In an immediate release, the pharmaceutical composition is released from the dosage unit into the subject or patient's body almost immediately. In a delayed release dosage unit, the pharmaceutical composition is delivered to the body with a delay after administration. In a sustained release or controlled release dosage unit, the dosage unit is designed to release the pharmaceutical composition at a predetermined rate to maintain a constant drug concentration over a specific period of time. The release profile of the dosage unit can be evaluated as documented in the major pharmacopoeias. For example, immediate release is defined by the European Medicines Agency as at least 75% of the active substance dissolves within 45 minutes (European Pharmacopeia (Ph. Eur.) 9th edition). In addition, however, it will be apparent to one of skill in the art that appropriate tests and time windows may vary depending on the therapeutic range of the drug substance, solubility and permeability factors.
[0168] In alternative embodiments, the administration method that can be considered in the context of the present invention is not particularly limited, so long as it provides systemic bioavailability. This includes, but is not limited to, oral, rectal, bronchial, nasal, buccal, sublingual, vaginal, transdermal, subcutaneous, uterine, or parenteral administration, or forms suitable for administration by inhalation or spray, including administration of powder and liquid aerosol. In a preferred embodiment, the administration method is oral administration. It is understood that oral administration includes administration by oral ingestion, but also includes administration modes such as buccal and sublingual administration, optionally by orodispersible dosage units, such as, but not limited to, orodispersible tablets. In all cases, the goal is to achieve the same effective dose of estetrol in plasma (e.g., the same AUC and / or Cmax value) as with oral dosage units.
[0169] In certain embodiments, the estetrol component is formulated into a unit dosage unit, including but not limited to hard capsules, soft capsules, tablets, coated tablets (such as coated tablets or sugar-coated tablets), granules, aqueous or oily solutions, syrups, emulsions, suspensions, inhalants or suppositories, and can be provided in any suitable packaging means known in the art, non-limiting examples being lozenges, sachets, packets, bottles, films, sprays, microcapsules, implants, rods or blister packs. In embodiments in which an effective amount of the estetrol component is administered by oral administration, the oral dosage unit according to the present invention is preferably a solid or semi-solid dosage unit, such as a tablet, capsule, cachet, pellet, pill, powder and granule. Particularly preferred compositions include a combination of estetrol monohydrate in the dosage disclosed herein and excipients suitable for solid or semi-solid dosage units.
[0170] The term "solid or semi-solid dosage unit" also includes capsules containing a liquid, such as oil, in which the estetrol component and / or optional progestogen component of the present invention is dissolved or dispersed. Tablets and equivalent solid and semi-solid dosage units can suitably contain materials such as binders (e.g., hydroxypropylmethylcellulose, polyvinylpyrrolidone (povidone, PVP), other cellulosic materials and starches), diluents (e.g., lactose (monohydrate) and other sugars, starches (e.g., corn starch), dicalcium phosphate and cellulosic materials), disintegrants (e.g., starch polymers and cellulosic materials (e.g., sodium starch glycolate)), and lubricants (e.g., (magnesium) stearates and talc). These tablets and equivalent solid dosage units can be prepared by any suitable means, which are well documented in the art (e.g., Kaur, Processing technologies for pharmaceutical tablets: A review, Int Res J Pharm, 2012). Non-limiting examples of processing the estetrol component when manufacturing dosage units include wet granulation using, for example, an aqueous or organic solution, direct compression, 3D printing, or coating the estetrol component onto carrier particles using an organic or inorganic solvent.
[0171] It is clear that a further aspect of the present invention relates to a pharmaceutical composition comprising an effective amount of an estetrol component for use in any medical indication disclosed herein. Treatment or prevention of a pain condition in a subject. The terms "formulation" or "composition" can be used interchangeably herein. It is clear that in any embodiment of one or more pharmaceutical or cosmetic compositions described herein, the composition can comprise one or more pharma- ceutically or cosmetically acceptable carriers (i.e., excipients). The term "pharma-ceutically acceptable" or "cosmetically acceptable" as used herein is consistent with the art and means compatible with other components of the pharmaceutical or cosmetic composition and not harmful to the recipient. In a particularly preferred embodiment of the present invention, the pharmaceutical composition according to the present invention is designed for daily administration, i.e., it represents a daily dosage unit. The excipients that can be used in the pharmaceutical composition are not particularly limited, and therefore include pharma- ceutical active ingredient excipients, binder excipients, carrier excipients, co-processed excipients, coating system excipients, controlled release excipients, diluent excipients, disintegrant excipients, dry powder inhalant excipients, effervescent system excipients, emulsifier excipients, lipid excipients, lubricant excipients, sustained release excipients, penetration enhancer excipients, permeation enhancer excipients, pH adjuster excipients, plasticizer excipients, preservative excipients, soluble The excipient may be one or more excipients selected from the group consisting of: stimulating agent excipients, solvent excipients, sustained release excipients, sweetener excipients, flavoring agent excipients, thickener excipients, viscosity modifier excipients, bulking agent excipients, compression excipients, dry granulation excipients, hot melt extrusion excipients, wet granulation excipients, fast release agent excipients, high bioavailability excipients, dispersion excipients, solubilization enhancing excipients, stabilizer excipients, capsule bulking excipients, or any combination thereof. Those skilled in the art will know that the use of such vehicles and drugs for pharmacoactive substances is common practice, and thus the incorporation of these excipients is known in the art. It is clear that all components used must be non-toxic at the concentration contained in the final pharmaceutical composition and must not adversely interfere with the activity of the estetrol component (which is preferably present as the main pharmacoactive component in the pharmaceutical composition).In certain embodiments, two or more excipients that one skilled in the art would classify as belonging to the same group of excipients are added to the pharmaceutical composition. In further embodiments, two or more excipients of different types that belong to different groups are added to the pharmaceutical composition. In certain embodiments, an excipient can perform more than one function and / or can be classified by one skilled in the art as belonging to different groups or types of excipients.
[0172] The compositions contemplated by the present invention may include additional skin active ingredients known in the art to provide skin care benefits. Skin care benefits may include, but are not limited to, benefits related to the cosmetic appearance of the skin. The additional skin active ingredients may provide immediate, short-term (i.e., acute) benefits and / or long-term, sustained (i.e., chronic) benefits.
[0173] While the present invention has been described in conjunction with detailed embodiments thereof, it is evident from the above description that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims. Aspects and embodiments of the invention disclosed herein are further supported by the following non-limiting examples.
[0174] The following specific experimental examples are provided in support of the claimed invention and should not be construed as limiting the scope of the invention. EXAMPLES
[0175] Example 1: Tissue distribution of estetrol after oral administration in a rat model [ 14 C]-estetrol was used to determine tissue distribution in female rats (partially pigmented and non-pigmented).
[0176] In non-pigmented female rats 14After a single oral dose of [C]-estetrol, radioactivity concentrations were generally maximal at the initial time point of 0.5 h, with the highest concentration measured in the liver (12.5 μg equivalents / g). Radioactivity was rapidly eliminated, so that by 24 h post-dose, apart from elements of the gastrointestinal tract and bladder, only the adrenal glands, kidneys, liver, pancreas, salivary glands, and thyroid gland were quantifiable.
[0177] [To partially pigmented female rats 14 After a single oral dose of [C]-estetrol, radioactivity concentrations were highest overall at the first time point 0.5 h after oral administration, with the highest concentration measured in the liver (13.7 μg equivalents / g). Radioactivity was also rapidly eliminated, reaching the BLQ (<0.076 μg equivalents / g) in most tissues by 24 h after administration. By 7 days after administration, all analyzed tissues, including melanin-containing structures (choroid, pigmented skin), except for the liver (0.410 μg equivalents / g), were below the limit of quantification.
[0178] Protocol - Tissue distribution study in non-pigmented rats Seven female Sprague-Dawley rats were each given 14 A single oral dose of [C]-estetrol was administered. At each selected time point (see below), one animal was sacrificed (by CO2 overdose) and immediately thereafter flash frozen in hexane / solid CO2. Carcasses were retained to examine tissue distribution of radioactivity using the technique of quantitative whole-body autoradiography (QWBA).
[0179] The times for analysis were 0.5 h, 1 h, 2 h, 5 h, 8 h, 24 h and 48 h.
[0180] After completion of whole-body autoradiography sectioning, the remaining carcasses were disposed of as waste.
[0181] Radioactivity distribution in tissues was determined and quantified using a Fuji FLA-5100 fluorescent image analyzer and associated Tina and SeeScan software. Radioactivity concentrations in tissues were determined using a calibrated autoradiography microscale made by GE Healthcare. A standard curve was generated using the microscale from which tissue concentrations of radioactivity (nCi / g) were determined. These values were then converted to μg equivalents / g using the specific activity of the administered formulation.
[0182] Protocol - Tissue distribution study in pigmented rats Groups of six female Lister hooded rats were each 14 A single oral dose of [C]-estetrol was administered. At each selected time point (see below), one animal was sacrificed (by CO2 overdose) and immediately thereafter flash frozen in hexane / solid CO2. Carcasses were retained to examine tissue distribution of radioactivity using the technique of quantitative whole-body autoradiography (QWBA).
[0183] The times for analysis were (0.5 h, 8 h, and 24 h, 7 days, 14 days, and 35 days).
[0184] Frozen carcasses were subjected to whole-body autoradiography.
[0185] Results in non-pigmented rats (focus on skin) When reporting concentrations, radioactivity is [ 14 C]-estetrol or [ 14 It was assumed that the radioactivity was related to any metabolites derived from [C]-estetrol. In all cases, the specific activity of the administered test compound was used to calculate concentrations. Radioactivity recovery is reported as a percentage of administered radioactivity (% dose). Similarly, radioactivity concentrations are reported as μg equivalents / g.
[0186] [ 14 The radioactivity concentrations in tissues (here, only skin) and tissue:blood ratios obtained from female Sprague-Dawley rats after a single oral dose of [C]-estetrol are shown in Tables 1 and 2, respectively.
[0187] Table 1: [in vivo] 14 Radioactivity concentrations in tissues (expressed as μg equivalents / g) following a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 2]
[0188] Table 2: [in vivo] 14 Tissue:blood ratios determined after a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 3]
[0189] Results in pigmented rats (focus on skin) [ 14 The radioactivity concentrations and tissue:blood ratios in tissues obtained from female Lister hooded rats after a single oral dose of [C]-estetrol are shown in Tables 3 and 4, respectively.
[0190] Table 3: [intracellular matrix complexes in partially pigmented female rats] 14 Radioactivity concentrations in tissues (expressed as μg equivalents / g) following a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 4]
[0191] Table 4: [intracellular matrix complexes in partially pigmented female rats] 14 Tissue:blood ratios determined after a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg [Table 5]
[0192] The total radioactivity in selected tissues / organs (obtained from Caster [2] and expressed as % dose / tissue, tissue % body weight) is shown in Table 5.
[0193] Table 5: [intracellular matrix complexes in partially pigmented female rats] 14 Total radioactivity in selected tissues following a single oral dose of [C]-estetrol at a nominal dose level of 15 mg / kg Results expressed as % dose / tissue [Table 6]
[0194] Conclusion: At the first sampling time (0.5 h), based on the total dose / tissue, radioactivity was present in pigmented and non-pigmented skin at >1% of the administered dose (1.7% and 1.1%, respectively). The results show that significant E4 concentrations were achieved in the skin after oral administration, indicating that estetrol was well-reached in the skin and would be therapeutically effective.
[0195] Example 2: Effect of estetrol (E4) in vitro on keratinocytes and fibroblasts, the two major cell types in the skin The aim of this study was to evaluate the effect of estetrol on the migration and proliferation capacity of human epidermal keratinocytes and human dermal fibroblasts in 2D culture and to directly compare the effects of this estrogen with estradiol (E2) as another reference estrogen.
[0196] This study consists in an in vitro assay aimed at evaluating the properties of E4 and E2 at four concentrations on keratinocytes and fibroblasts, respectively. The assay involves the measurement of colony formation on standard cell-free surfaces generated from confluent monolayers of cells using a dedicated culture device (IBIDI chamber). The assay is performed in the presence and absence of proliferation inhibitors to focus on cell proliferation and migration, or migration only, respectively.
[0197] methodology Cell model - normal human epidermal keratinocytes (NHEK) Studies were performed using cultures of normal human foreskin-derived epidermal keratinocytes (NHEK, Lonza). Cells were grown in serum-free Epilife medium (ThermoFisher Scientific) supplemented with Human Keratinocyte Growth Supplement (HKGS, ThermoFisher Scientific) and antibiotics. Cells were maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere.
[0198] Cell model - Normal human dermal fibroblasts (NHDF) Normal human foreskin-derived dermal fibroblasts (NHDF, ATCC) were grown in phenol-free Dulbecco's modified Eagle's medium (DMEM, ThermoFisher Scientific) supplemented with 10% fetal bovine serum (FBS, ThermoFisher Scientific), L-glutamine, and antibiotics. Cells were maintained in a humidified incubator at 37°C in a 5% CO2 atmosphere.
[0199] Assays and Analysis Cells were plated in 2-well silicone inserts with a defined cell-free gap (IBIDI chambers: IBIDI GmbH, 80209) previously inserted into 12-well culture plates. This culture device allows the creation of a standardized cell-free gap of 500 μm ± 100 μm for monitoring cell colony formation. 24 hours after seeding, when the cultures reached high confluence, the cells in the inserts were treated with mitomycin C (MMC) at 10 μg / mL for 2 hours or not. After these 2 hours, the inserts were removed and the cells were treated with E2 or E4 with or without MMC for another 2 hours. Then, if necessary, the culture medium was removed and the cells were treated with E2 or E4 without MMC for 22 hours.
[0200] For the assay, keratinocytes were plated in Epilife medium without HKGS and all treatments were performed in this medium. Fibroblasts were plated in DMEM medium containing only 2.5% FBS and treatments were performed in the absence of FBS.
[0201] E2 and E4 were each administered at four concentrations (10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M) In parallel, cells were treated with positive controls (HKGS 1% for human keratinocytes and 10 ng / ml PDGF-BB for human fibroblasts).
[0202] To monitor cell colony formation and evaluate the gap closure rate, pictures of the gaps were taken at different time points: 0 h (corresponding to the beginning of treatment with E2 or E4 and removal of the culture insert), 6 h and 24 h (corresponding to the end of treatment with E2 or E4). Pictures were taken with a microscope Zeiss (Axiover 25-10× objective) and a camera Invenio2EIII (DeltaPix - Lux-Optic). The colony-forming area was quantified from the pictures using the WimAsis platform - WimScratch software. Three pictures were taken for each insert at each time point. Three repetitions were performed for each condition, which means a total of nine pictures for each condition and each acquisition time point.
[0203] result Normal human epidermal keratinocytes (NHEK) Treatment with HKGS, used as a positive standard, allowed a significant increase in the colony-forming area in the presence and absence of MMC, thus validating the test.
[0204] In the presence of proliferation inhibitor (MMC), 10 -7 M and 10 -10E4 in M significantly increased colony formation in cell-free areas compared to the ethanol control at 24 hours after treatment, indicating stimulation of cell migration (Figure 1). -7 M and 10 -10 E4 at concentrations of M significantly increased colony formation in cell-free areas compared to the ethanol control (Fig. 2 ).
[0205] In either the presence or absence of a proliferation inhibitor (MMC), E2 failed to significantly increase colony formation in cell-free areas compared to the ethanol control (Figures 3 and 4). -7 M~10 -9 M concentration range, after 24 hours of treatment, it even appears to have an inhibitory effect on gap closure. This inhibition was -8 It was significant only for the concentration of M.
[0206] Normal human dermal fibroblasts (NHDF) Treatment with PDGF-BB at 10 ng / ml, used as the positive standard, significantly increased the colony-forming area both in the presence and absence of MMC, thereby validating the test.
[0207] In the absence of a proliferation inhibitor (MMC), E4 was unable to significantly increase colony formation in cell-free areas (Figure 6). However, in the presence of MMC at 24 h, 10 -7 M and 10 -8 E4 in M was able to significantly increase colony formation in cell-free areas compared to the ethanol control (Fig. 5 ).
[0208] In the presence of a proliferation inhibitor (MMC), E2 was unable to significantly increase colony formation in cell-free gaps (Figure 7). However, in the absence of MMC at 24 h, 10 -7 M, 10 -8 M and 10 -10 E2 in M increased colony formation in cell-free areas compared to the ethanol control (Fig. 8 ).
[0209] conclusion In this study, the inventors -7 M and 10 -10 We noticed that E4 in M significantly increased the surface colonized by keratinocytes in culture over time. This effect was significant after 6 and 24 hours of treatment in the absence and presence of MMC, respectively. Thus, E4 may have a stimulating effect on cell proliferation as observed after 6 hours of treatment, but may also induce keratinocyte migration after a certain delay, given the differences observed in the colonized surface after 24 hours in the presence of proliferation inhibitors. In the presence of E2, no significant effect on keratinocyte proliferation or migration could be observed.
[0210] E4 and E2 showed significant activity on fibroblast cultures after 24 hours of treatment. E4 rather acted on cell migration, whereas E2 (10 -7 M and 10 -8 M), E2 appeared to have a specific effect on fibroblast proliferation (10 -7 M, 10 -8 M, and 10 -10 The results are summarized in Table 6 below.
[0211] Table 6: Activity of estetrol (E4) or estradiol (E2) on keratinocytes (NHEK) and fibroblasts (NHDF) [Table 7]
[0212] Example 3: Effects of E4 on keratinocytes, fibroblasts, and immune cells in wound healing in an in vitro model The acute wound response involves a variety of cell types that are both activated locally and recruited from the periphery. In this pilot study, the effects of E4 on multiple wound-associated cell types (keratinocytes, fibroblasts, and immune cells) were directly compared to those of E2.
[0213] Keratinocyte and fibroblast experiments protocol Human skin was delivered to the laboratory in holding medium (DMEM containing 4% penicillin-streptomycin and amphotericin B solution) within 30 minutes of harvest. Once degreased, the skin was rinsed with HBSS containing 4% PSA, then with DPBS without antibiotics, then cut into thin strips and floated on 0.2% Dispase II in DPBS overnight at 4°C, after which the epidermis was manually separated from the dermis. Primary human epidermal keratinocytes and primary human dermal fibroblasts were then isolated.
[0214] Confluent wells of both primary keratinocytes and fibroblasts were subjected to a highly validated scratch wound procedure (using a 1 mL sterile filter tip). After scratching, cells were rinsed with DPBS and cell-specific medium containing treatments was added to each well. Cells were imaged on a ptychographic live cell imaging platform (Livecyte 2™, Phasefocus) for 24-48 hours. Automated tracking of individual unlabeled cells was combined with 3D cellular measurements to quantify various wound-associated cellular parameters, including scratch closure rate.
[0215] E4(10 -10 M~10 -6 Dose range-finding experiments were performed with E2, in the presence and absence of mitomycin C (MMC, to inhibit proliferation), and with vehicle as a negative control.
[0216] Fibroblasts – Results Using a widely validated in vitro fibroblast monolayer scratch assay, we demonstrated that E4 promotes in vitro wound closure in both mouse and human fibroblasts to the same extent as E2 (Figures 9A and 9B, respectively). Assays were performed in phenol red-free cell culture medium containing charcoal-stripped fetal bovine serum using fibroblasts isolated from C57Bl / 6 female mice and fibroblasts isolated from surplus abdominal skin from three female donors aged 20, 49, and 57 years.
[0217] Keratinocytes - Results The data show that the effect of estrogens (E4 and E2) on keratinocyte migration was dependent on the percentage of HKGS (Human Keratinocyte Growth Supplement) used in the culture medium. However, under culture conditions containing 15% HKGS, there was no effect of E4 (10 -10 M and 10 -7 The effect of M) appears to be greater than that of E2 (Figure 10).
[0218] Immune cell experiments Immune cell polarization was assessed in vitro in human and mouse monocytes (BMDM bone marrow-derived monocytes) using markers of M1 / TH-1 (NOS2) and M2 / TH-2 (ARG1) phenotypes.
[0219] protocol Human blood was collected under national ethical approval and with full written patient consent. Freshly isolated human blood was collected in EDTA vacutainer tubes, diluted 1:1 with PBS, and gently layered on histopaque (Merck). Immediately after centrifugation at 100×g for 30 min, the whitish buffy coat formed at the histopaque interface was aspirated and washed twice with sterile PBS (centrifugation at 100×g for 10 min). Non-contact classical monocytes (CD14++, CD16−) were isolated from the washed buffy layer cells using the Miltenyi Classical Monocyte Isolation Kit, LS columns, and MidiMACs separators (Miltenyi). Isolated cells were seeded on tissue culture plates and stimulated to differentiate with PMA.
[0220] Experiments were performed to evaluate the anti-inflammatory effects of E4 or vehicle (negative control). qPCR methodology was used to evaluate the effect of E2 and E4 on immune cell polarization using well-validated markers of pro-inflammatory (NOS2 for MI / TH-1 phenotype) and anti-inflammatory (ARG1 for ME / TH-2 phenotype).
[0221] result E4 exhibited anti-inflammatory effects and promoted the switch of mouse BMDMs (bone marrow derived monocytes) or human monocytes from subtype M1 (pro-inflammatory) to subtype M2 (healing), results are shown in Figures 11A and 11B, respectively.
[0222] Example 4: Effect of E4 on gene expression in keratinocytes and fibroblasts in an in vitro model of wound healing The healing properties of E4 were investigated at the transcriptional level by studying gene expression changes by RT-qPCR. 84-gene qPCR arrays focused on the wound healing process were used. These arrays contain genes important in the three phases of the wound healing process, including extracellular matrix (ECM) remodeling factors, inflammatory cytokines and chemokines, as well as growth factors and key signaling molecules. To highlight the potential utility of E4 on wound healing, the changes in gene expression were interpreted in a dermocosmetic context.
[0223] Cell treatment 25 cm 2 After seeding in culture flasks (T25) for 24 h, the cells were treated with E4 for 15 h. Culture conditions were identical to those used for the scratch test (see Example 2), and the cells were treated with E4 in the absence of FBS / HKGS. The cell density used for the gene expression assay was lower than that used for the scratch test, being 113636 cells / cm for keratinocytes in the culture inserts of the wound closure assay. 2 , and 100,000 cells / cm for fibroblasts. 2 15,800 cells / cm for gene expression assays 2 In practice, gene expression analysis is usually performed on under-confluent cells (during logarithmic growth phase).
[0224] Total RNA extraction 10 -7 At the end of the 15-h treatment with E4 or ethanol 0.1% used as a control, total RNA was extracted using the Qiagen RNeasy kit (Qiagen). Cells were rinsed with cold PBS and lysed in the appropriate buffer provided with the kit. Extraction was performed according to the supplier's recommendations. Harvested RNA was stored at -80°C.
[0225] RNA integrity analysis RNA concentration was determined by spectrophotometric measurement (QIAxpert, Qiagen) and RNA quality was analyzed by capillary electrophoresis (Agilent Bioanalyzer 2100-Agilent RNA 6000 Nano Kit).
[0226] cDNA synthesis Reverse transcription was performed from total RNA using the kit "RT2 First Strand Kit" (Qiagen) according to the manufacturer's instructions.
[0227] Quantitative PCR using RT2 Profiler PCR arrays To quantify the expression changes of specific markers in the cDNA population, we used the qPCR method. The RT2 Profiler PCR Array Human Wound Healing contains specific primers for 84 target genes.
[0228] Amplification of the target genes was performed according to the supplier's recommendations using "HotStart Taq DNA Polymerase" and SYBR Green as the detection method. SYBR Green is a marker that fluoresces when intercalated between nucleic acid base pairs. Thus, the fluorescence intensity is directly proportional to the amount of amplicon produced. qPCR was performed using the Quantstudio7 Real-Time PCR System (Applied Biosystems) and its software (QuantStudio Real-Time PCR Software v1.3, Software, Applied Biosystems).
[0229] Data obtained for the E4-treated condition was compared to the ethanol control in both cell types. Threshold cycle (Ct) values were normalized to the average Ct values of several housekeeping genes present on the array (shown in the table below). The maximum Ct cutoff value was fixed at 36 cycles, meaning that Ct values above 36 were not considered in the analysis.
[0230] result Human keratinocytes (Table 7) or fibroblasts (Table 8) were cultured at 10 -7 Treatment of M with E4 for 15 h induced certain interesting pathways involved in different phases of the wound healing process.
[0231] Table 7: List of genes whose expression changed after 15 hours of treatment with estetrol (E4) in cultured human epidermal keratinocytes - expressed as fold change (FC) relative to the ethanol control: FC>1: increase - FC<1: decrease [Table 8]
[0232] Table 8: List of genes whose expression changed after 15 hours of treatment with estetrol (E4) in cultured human dermal fibroblasts - expressed as fold change (FC) relative to the ethanol control: FC>1: increase - FC<1: decrease [Table 9]
[0233] Although small in number and amplitude, these changes in gene expression (compared to ethanol controls) suggest that E4 may promote the switch between inflammatory and proliferative / remodeling phases via downregulation of proinflammatory factors and stimulation of the coupled MMP / TIMP system.
[0234] Human fibroblasts or keratinocytes were cultured at 10 -7 Treatment of M with E4 for 15 h significantly reduced the expression of chemokines CXCL5 and CXCL11, cyclooxygenase 2 (PTGS2), and fibroblast growth factor 2 (FGF2), and enhanced the switch to the proliferative phase.
[0235] Example 5: Evidence for the antioxidant properties of E4 The purpose of this study was to identify mouse lymphoma cell line L5178Y TK + / - The objective of this study was to investigate the generation of reactive oxygen species (ROS) induced by the test product estetrol (E4) in rats.
[0236] protocol L5178Y TK in logarithmic growth phase + / - Cells were plated in black 96-well cell culture plates at 1 × 10 in 90 μL of cell culture medium. 4 The wells were plated with cells. Control and test articles were applied to the cells as 10x concentrates in 10 μL of 10% ethanol in PBS (final concentration of ethanol on the plate was 1%) in triplicate. The cells were incubated at 37°C, 5% CO2 for 3 hours and ROS generation was assessed by fluorescence using ROS reagent, which was freshly prepared by dissolving 1 ampoule (50 μg) of reagent in 70 μL DMSO and further diluting this in 2.1 mL of pre-warmed PBS. 10 μL of ROS reagent was added to each well and the plate was shaken in the dark for 30 seconds. The plate was incubated at approximately 37°C, 5% CO2 for 1 hour and 30 minutes and the fluorescence was read on a plate scanner with excitation at 492 nm and emission at 520 nm.
[0237] Three experiments were performed using negative control lactate (known not to induce ROS) and positive control hydrogen peroxide (known to increase ROS in cells) at concentrations up to 100 μM, and test article at concentrations of 1 μM, 10 μM, 50 μM, 100 μM, 1000 μM, and 3000 μM. ROS induction results for cells treated with the negative control, positive control, and test article were compared to those obtained with the untreated vehicle control.
[0238] result The negative control, lactate, did not induce ROS in any experiment at concentrations up to 100 μM when compared to the vehicle control. The positive control, hydrogen peroxide, showed a trend toward increased ROS levels after 3 hours of exposure when compared to the vehicle control.
[0239] Up to 3000 μM E4, L5178Y TK + / -Lactate caused a dose-dependent decrease in ROS detected in cells, whereas lactate up to 100 μM had no effect on ROS induction after 3 h exposure.
[0240] conclusion E4 caused a dose-dependent decrease in ROS levels in all three experiments, with the highest concentration tested (3000 μM) showing the greatest effect, suggesting that E4 acted as an antioxidant in this study.
[0241] Example 6: In vitro research study design This series of experiments allows identifying the effects of E4 on some of the most important aspects of skin ageing, such as epidermal and keratinocyte biology (skin barrier, moisturization, lipid synthesis, melanogenesis, proliferation), dermal and fibroblast biology (extracellular matrix component production, glycosaminoglycan synthesis, moisturization), antioxidant and anti-inflammatory properties, sebum production, and pigmentation.
[0242] 1) Transcriptome analysis The transcriptome analysis is based on reverse transcription quantitative PCR using TLDA (TaqMan Low Density Array) technology. Specific target genes are identified and divided into multiple research questions, and 48 to 96 transcripts per research question are simultaneously amplified. This is performed using RNA extracted from either NHEKs (normal human epidermal keratinocytes) or NHDFs (normal human dermal fibroblasts) depending on the research question.
[0243] By this method, the ability of a treatment to modulate the expression of genes involved in a specific biological function can be identified.
[0244] method: NHEK or NHDF were administered with vehicle or 10 -7 After 24 h treatment with E4 in M, RNA is isolated and subjected to reverse transcription. TLDA will be conducted on the following research questions:
[0245] [Table 10]
[0246] Gene expression in the presence of E4 is expressed as fold change compared to vehicle.
[0247] Expected Results: Preliminary results indicate that E4 regulates keratinocyte and fibroblast activity. This transcriptome analysis will reveal a set of genes whose expression is up- / down-regulated by E4 treatment.
[0248] 2) Functional Test Part 1 - Oxidative Stress and Inflammation Exposure to UV rays from sunlight and environmental pollutants is known to play an important role in skin aging, which leads to the accumulation of oxidative molecules, the overproduction of reactive oxygen species (ROS), and the induction of pro-inflammatory responses. Skin aging is also characterized by remodeling of the ECM (extracellular matrix) and a decrease in the production of key components such as collagen or hyaluronic acid.
[0249] This functional test allows identification of the ability of a treatment to protect the skin from these adverse effects.
[0250] method: NHEKs and NHDFs are treated with six different conditions: (1) basal condition-vehicle; (2) basal condition-E4 treatment; (3) basal condition-E2 treatment; (4) exposure to UV light and / or urban dust-vehicle; (5) exposure to UV light and / or urban dust-E4 treatment; (6) exposure to UV light and / or urban dust-E2 treatment. Assessment of oxidative stress: quantification of ROS production. Assessment of inflammatory response: quantification of cytokine release (e.g. IL-1α, IL-6, IL-8, TNF-α, PGE2) by ELISA. Assessment of ECM modeling (for NHDF only): Detection and quantification of ECM components (e.g., collagen type I, collagen type III, hyaluronic acid, etc.) by ELISA or immunostaining.
[0251] Expected Results: a) Basal conditions allow the evaluation of the effect of E4 treatment on the production of ECM components. It is expected that E4 will modulate this composition and promote the production of collagen and hyaluronic acid, which is of interest in the context of skin ageing, since the production of these components naturally declines with age, resulting in increased skin thickness and reduced hydration. b) Preliminary results have revealed antioxidant and anti-inflammatory properties of E4 in several models, and it is hoped that this functional testing will observe the same properties for skin, which is of particular interest in the context of skin aging, since oxidative stress and inflammation play important roles in this process. c) Comparison with E2 treatment can indicate whether E4 is more potent in antioxidant and / or anti-inflammatory properties. Based on preliminary results, this is expected to be the case.
[0252] 3) A detailed overview of the effect of E4 on IL-6 release from NHEK cells Materials and Methods 1. Cell model: normal human epidermal keratinocytes (NHEK) Normal human foreskin-derived epidermal keratinocytes (NHEK, Lonza, 00192906) isolated from the foreskins of three Caucasian donors were grown in Epilife medium (Fisher Scientific, M-EPI-500-A) supplemented with Human Keratinocyte Growth Supplement (HKGS, Fisher Scientific, S-001-5) and antibiotics (gentamicin, Fisher Scientific, 15710-049). Cells were maintained in a humidified incubator at 37°C with a 5% CO2 atmosphere.
[0253] 2. Preparation of test articles for cell treatment E4 and E2 (prepared as powders) were dissolved in 100% ethanol at 0.1 M. This was then further diluted with ethanol and medium to the appropriate concentration. Each preparation of E4 and E2 did not exceed 0.1% ethanol as a final concentration in the culture medium. In practice, 1000-fold concentrated stock solutions were prepared in 100% ethanol, aliquoted, and stored at -20°C until application to cells.
[0254] Because plastic products may have estrogenic activity (Miraldi et al., Arch Intern Med, 2006), all solutions were prepared in glass vials and kept protected from light.
[0255] 3. Induction of inflammation in NHEKs To induce IL-6 release, NHEKs were exposed for 24 h with 10 ng / mL phorbol myristate acetate (PMA) in combination with 2 μM calcium ionophore A23187 (Sigma Aldrich, C5722). Treatment with test or reference products was performed simultaneously with inflammatory challenge. NHEKs were treated in Epilife medium without hydrocortisone or phenol red. E4 was administered for 10 min at 4°C. -4 M, 10 -5 M, 10 -6 M, 10 -7 M, and 10 -8 Apply it to M, E2 is 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, and 10 -9 M. 0.1% EtOH was tested as a solvent control. 10 μM dexamethasone was used as an anti-inflammatory standard. At the end of the 24 h treatment, the supernatants were collected and stored at -20°C, and cell viability assays were evaluated by MTS (see item 5). A summary of the treatment kinetics is shown in Figure 12. All treatments were performed in triplicate (n=3).
[0256] 4. Quantification of inflammatory mediator release from NHEKs Quantification of the release of inflammatory markers was performed using specific ELISA kits according to the supplier's specifications and based on a standard curve, after which the results obtained were normalized to the corresponding cell viability (obtained by MTS assay).
[0257] Supplier reference numbers of kits used for IL-6 quantification are as follows: IL-6, BioTechne, D6050;
[0258] 5. Cell Viability Assay with MTS At the end of treatment and collection of culture medium, cell viability was assessed using the MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay. The effect of treatment was compared to untreated control conditions and to a solvent control (EtOH 0.1%). Viability data was used to normalize the amount of released inflammatory mediators.
[0259] result Effect of test articles on PMA / A23187-induced IL-6 release from NHEKs NHEKs were treated as described in the methodology section. IL-6 was quantified by ELISA from harvested supernatants according to the kit provider's instructions. Only three concentrations of test article (selected according to the sponsor according to the results of the viability assay) were evaluated by ELISA.
[0260] PMA / A23187 significantly increased IL-6 release from NHEKs, and dexamethasone inhibited this effect (Figure 13). These results confirmed that the cells responded correctly to the treatment.
[0261] The three doses tested (10 -5 M, 10 -6 M, and 10 -7M) E4 significantly and strongly reduced IL-6 release compared to the stimulated 0.1% EtOH condition. In fact, the level of IL-6 release from NHEKs treated with PMA / A23187+E4 was comparable to that of NHEKs treated with PMA / A23187+dexamethasone. On the other hand, IL-6 release was not affected by E2 treatment.
[0262] conclusion In NHEKs, three concentrations were tested (10 -5 M, 10 -6 M, and 10 -7 M) E4 strongly and significantly reduced PMA / A23187-induced IL-6 release, an effect that was not observed with E2.
[0263] 4) Functional test 2 - Psoriasis Psoriasis is a complex skin disease in which Th17 and Th22 immune cells play a key role. Two of the main characteristics of this pathology are the production of proinflammatory cytokines, and the hyperplasia and altered differentiation of epidermal keratinocytes. Some symptoms of psoriasis may increase during menopause.
[0264] This functional test allows identifying treatments capable of reducing symptoms associated with inflammation and keratinocyte dysfunction. It is divided into two models: Model 1 - Inflammation: This model mimics the inflammatory state of psoriasis. Model 2 - Keratinocytes: This model mimics keratinocyte dysfunction in psoriasis, including hyperplasia and abnormal thickening of the epidermis.
[0265] method RHE (reconstructed human epidermis) was presented with either a Th17 cytokine cocktail (model 1) or a Th22 cytokine cocktail (model 2) in the presence of vehicle or E4 treatment. Assessment of the inflammatory response: quantification of the expression of inflammatory biomarkers using several techniques such as ELISA, immunostaining, RT-qPCR, or TLDA. Assessment of keratinocyte function: histological analysis (cell and tissue morphology, epidermal thickness, keratinocyte proliferation, etc.).
[0266] Expected Results: a) Preliminary results reveal anti-inflammatory properties of E4 in several models, and it is hoped that this functional testing will observe the same properties for psoriatic features. b) Preliminary results reveal a role for E4 in basal proliferation of keratinocytes. It will be interesting to see if this also applies in inflammatory conditions such as in psoriasis. It is hoped that E4 may regulate alternative keratinocyte functions in a way that favors the reduction of psoriatic symptoms.
[0267] 5) Functional test 3 - Sebum production Sebum is produced in the sebaceous glands of the skin. Sebum plays an important role in moisturizing the skin, and its production is known to decrease during menopause.
[0268] This functional test allows the determination of the ability of a treatment to stimulate sebum production.
[0269] method: Sebocytes are subjected to vehicle or E4 treatment. Lipid production is assessed by tissue staining such as Oil Red O.
[0270] Expected Results: It is expected that E4 treatment will promote lipid production by sebocytes.
[0271] 6) Functional test 4 - Pigmentation Skin pigmentation depends on the function of melanocytes. During menopause, the skin may become unevenly pigmented and may appear blotchy.
[0272] This functional test allows the identification of the ability of a treatment to modulate melanin production by melanocytes.
[0273] method: Melanocytes are subjected to vehicle or E4 treatment. Melanin content is assessed by histological techniques such as Fontana-Masson staining or colorimetry.
[0274] Expected Results: The potential effect of E4 on melanocytes was studied to assess whether it increases or decreases melanin production, which has implications for clinical significance.
[0275] Example 7: Intrinsic senescence of human dermal fibroblasts Skin aging is a multifactorial process resulting from both intrinsic factors (genomic, hormonal, etc.) and exogenous aggravating factors. Intrinsic aging can be modeled using the Hayflick model, an in vitro model of replicative senescence / cellular senescence obtained by successive replicative cycles. According to this model, cultured fibroblasts are considered "senescent" after a certain number of divisions and eventually enter a state of replicative cellular senescence accompanied by the cessation of cell proliferation.
[0276] “Aged” human dermal fibroblasts were cultured in a 10 -6 M, 10 -7 M or 10 -8 M) or vehicle for 24 hours, RNA was extracted and subjected to reverse transcription, and the expression of 64 genes involved in skin aging (ECM composition and production, cell-cell or cell-ECM interactions, ECM turnover, growth factors, cytoskeleton, cell cycle, apoptosis, inflammation, oxidative stress, etc.) was quantified by quantitative PCR.
[0277] It is expected that E4 treatment will result in modulation of gene expression that is favorable for reduced aging.
[0278] Example 8: Antioxidant properties in tubo The antioxidant capacity of E4 is evaluated using SKIN-BIOSENSE™ technology, an electrochemical sensor that allows the assessment of the balance between oxidative and antioxidant compounds.
[0279] The E4 solution is contacted with the H2O2 solution and the H2O2 signal is measured after 30 minutes at baseline. The antioxidant index of E4 is assessed based on the decrease in the H2O2 signal.
[0280] It is expected that strong antioxidant properties will be seen for E4.
[0281] Example 9: In vivo study design protocol The most commonly used animal model of human menopause consists of the induction of estrogen deprivation by performing a bilateral oophorectomy.
[0282] Human oral E4 treatment will be replicated by either oral administration or by use of subcutaneous sustained release pellets. E4 concentrations and duration of treatment will be determined based on preclinical and clinical data and depending on the parameters measured.
[0283] Survey parameters Extracellular matrix composition (collagen, elastic fibers, glycosaminoglycans and hyaluronic acid) (Voloshenyuk et al., Am J Physiol Regul Integr Comp Physiol. 2010 Aug;299(2):R683-93; Roeck et al., J Biol Chem. 2012 Jun 8;287(24):20056-69; Saville et al., preprint bioRxiv 728865) Moisturizing (glycosaminoglycans and hyaluronic acid, sebum production, skin barrier function) (Roeck et al., J Biol Chem. 2012 Jun 8;287(24):20056-69, Chen et al., Exp Dermatol. 2017 May;26(5):394-401, Sorop et al., Rom J Morphol Embryol. 2020 Jul-Sep;61(3):879-88) Oxidative stress (ROS production, antioxidant enzyme activity) (Kasimay et al., Ren Fail. 2009;31(8):711-25, Baeza et al., Biogerontology. 2010 Dec;11(6):687-701) Inflammation (pro-inflammatory cytokine production) (Yoon et al., J Invest Dermatol. 2014 Aug;134(8):2290-2293, Watanabe et al., Toxicol Appl Pharmacol. 2018 Sep 15;355:226-237) Psoriasis (Wang et al., Int Immunopharmacol. 2019 Apr;69:270-278, Iwano et al., J Appl Toxicol. 2020 Oct;40(10):1353-1361) Sebum production (Mii et al., Am J Pathol. 2012 Oct;181(4):1180-9, Dahlhoff et al., Exp Dermatol. 2013 Oct;22(10):667-9, Ebel et al., Biochem J. 2014 Jul 1;461(1):147-58) Pigmentation (Kumar et al., Biofactors. 2013 May-Jun;39(3):259-70, Sorop et al., Rom J Morphol Embryol. 2020 Jul-Sep;61(3):879-88)
[0284] Example 10. In vitro / mouse evaluation of skin aging The overall aim of this study is to evaluate the effect of E4 on skin aging using a combination of in vivo and in vitro models. In detail, in aged female mice, subcutaneous mini-osmotic pumps will be used to deliver E2 or E4 over a period of 3 weeks to evaluate the effect of estrogenic compounds on skin aging and wound healing (Objective 1). Mini-osmotic pumps have already been described by Gallez et al. (Cancers (Basel), 2021) and represent an accepted model that mimics oral administration in humans, since similar plasma concentrations can be achieved. At the end of the 3 weeks, the effect of E4 supplementation on aged skin will be evaluated in detail. Complementary in vitro experiments (Objective 2) will be performed in parallel with the in vivo studies to determine the direct effect of E4 on a) extracellular matrix (ECM) deposition, matrix metalloproteinase (MMP) activity, and antioxidant activity in human dermal fibroblasts, and b) aging and differentiation of human epidermal keratinocytes.
[0285] Aim 1: In vivo evaluation of the effects of E4 on aging skin and wound healing Compound Administration Estetrol (E4), 17β-estradiol (E2) or vehicle are delivered using mini-osmotic pumps.
[0286] Animal testing Aged (18 months old) wild type female mice (C57BL / 6J) are fed standard chow and water ad libitum. Mice are maintained at defined temperature and humidity with a 12-h light / dark cycle. Animals are anesthetized (oxygen, isoflurane and nitrous oxide) and mini-osmotic pumps are implanted on the back. Animals are collected in a heated cabinet and returned to an unused cabinet containing alpha pads, RO water, chow, mash and bedding. Observations are performed post-operatively and non-invasive ultrasound imaging and skin elasticity measurements (dermalab, cortex technologies) are performed on days 0, 5, 10, 15 and 20 after implantation (throughout the life phase of the study) to allow real-time assessment of relative changes in skin thickness and ECM properties. 14 days after implantation, mice are anesthetized and a 2x6 mm dorsal excision wound is created (sterile biopsy). Excised skin is taken for histological evaluation (paraffin-embedded histology and frozen histology, see below). Mice are returned to housing for ongoing evaluation. Twenty-one days after implantation (seven days after wounding), mice are euthanized and additional dorsal and abdominal skin samples are taken for histological evaluation and biomechanical testing, respectively.
[0287] Mice were divided into five treatment groups (six mice per group): 1) Placebo 2) 0.1 mg / kg / day of E2 3) 0.1 mg / kg / day of E4 4) 0.3 mg / kg / day of E4 5) 1 mg / kg / day of E4
[0288] Tissue processing and analysis 21 days after implantation, mice are euthanized by CO2 augmentation and cardiac puncture, and dorsal and abdominal skin samples are harvested. Excised skin (14 days after wounding) and dorsal skin samples (harvested on day 21) are processed for paraffin-embedded histology, which allows a detailed characterization of the effect of E2 / E4 on skin aging (epidermal and dermal thickness, basement membrane, dermal ECM composition). ECM fiber maturity is determined using picrosirius red staining (Wilkinson et al., J Invest Dermatol, 2019, Nov;139(11):2368-2377.e7) and elastic fiber distribution is revealed by Van Gieson. Wound and dorsal skin samples are also processed for cryohistology (OCT) to characterize cellular senescence (SA-bGAL staining; Wilkinson et al., J Invest Dermatol, 2019, May;139(5):1171-1181.e6). Additional dorsal skin is snap frozen in liquid nitrogen and RNA is isolated to evaluate dermal aging markers (e.g., Cdkn1a, Cdkn2a). Abdominal skin is subjected to biomechanical testing to determine breaking strength and evaluate biomechanical parameters. Wound healing analysis also evaluates differences in wound closure between treatments (Figure 14).
[0289] Objective 2: Complementary in vitro studies to explore mechanisms of action In parallel with the in vivo experiments, in vitro studies will assess the effects of E4 on specific aspects of skin biology.
[0290] a) Human dermal fibroblasts ECM deposition assay ECM deposition is assessed in human dermal fibroblasts (HDFs) isolated from aged human skin (Wilkinson et al., 2019, Nov;189(11):2196-2208). HDFs are isolated from three elderly skin donors (female, 60+), passaged and expanded in optimized phenol red-free cell culture medium. HDFs are cultured in the following media: vehicle, E2 (10 -6 M~10- 9 M), or E4(10 -6 M~10-9 M) and with and without stimulation of ECM deposition. Extracellular ECM deposition assays are performed for 11 days, while intracellular ECM production is assessed on day 3 (Figure 15A). To assess ECM production, cells and deposited ECM are fixed, followed by independent quantification of fibronectin, collagen I, and collagen III using immunofluorescence staining and confocal microscopy. These studies explore the ability of E4 to promote new matrix production by senescent cells.
[0291] MMP activity MMPs (especially MMP1, MMP2, and MMP9) are associated with increased matrix turnover in aged skin. HDFs were isolated from three elderly skin donors (female, 60+, as above) and treated with vehicle, E2 (10 -6 M~10 -9 M), or E4(10 -6 M~10 -9 HDFs are treated with E4 (E4+) for 24-72 h. MMP expression in HDFs is assessed by qPCR using MMP-specific primers. MMP activity is determined by zymography using medium harvested from cultured HDFs (as described in Wilkinson et al., 2019b,c) (see Figure 15B). These studies explore the ability of E4 to suppress ECM turnover.
[0292] Antioxidant activity The beneficial effects of E2 on skin aging are mediated, in part, by cellular antioxidant activity. To quantify the antioxidant effect of E4 (relative to E2), two independent approaches are used. First, a quantitative high-throughput cellular antioxidant assay (CAA, as described in Wolfe & Liu, J agric Food Chem, 2007) was used to measure the antioxidant activity of E2 (10 -6 M~10 -9 M) or E4(10 -6 M~10 -9First, to determine the ability of E2 / E4 (E2+E4 ...
[0293] b) Human epidermal keratinocytes Effect on cellular aging At the population level, aged epidermal keratinocytes display a reduced proliferative capacity, high levels of cellular senescence, and reduced contribution to specific epidermal functions, such as tissue regeneration, terminal differentiation, and skin moisturization. In this study, the effect of E4 on specific aspects of epidermal aging is evaluated in primary epidermal keratinocytes from three donors (female, 60+). Cells are grown and passaged on matrix-coated plates in CnT-AG2 VitroAge Keratinocyte Senescence Medium (CellnTec). For all assays, cells are cultured in E2 (10 -6 M~10 -9 M), E4(10 -6 M~10 -9 M), or vehicle and evaluated for up to 2 weeks. The effect of E2 / E4 on intrinsic keratinocyte senescence in vitro will be evaluated by a) determining comparative growth curves with and without E2 / E4 treatment, and b) performing SA-bGAL staining to quantify population cell senescence. The effect of E2 / E4 will also be evaluated on gene expression related to proteins important for skin hydration / moisturization (e.g. AQP3, CD44, E-cadherin) (Choi et al., Molecules, 2019). These studies will explore the possibility that E4 may result in functional improvements in senescent human epidermal cells.
[0294] Expected Results: a. Survival phase of the study: Real-time assessment of skin thickness and ECM deposition shows improvements over time compared to day 0 of treatment.
[0295] b. Detailed histological, biochemical, and biomechanical characterization: The uterotrophic effect of treatment with E4 is limited or even completely abolished compared to treatment with E2. Paraffin-embedded histology shows a beneficial effect of the treatment on skin aging (epidermal and dermal thickness, basement membrane, dermal ECM composition).
[0296] The ECM fibers are less mature and the distribution of elastic fibers shows improvement in the treated group.
[0297] Cellular senescence is less pronounced in the treated groups and the expression of cutaneous aging markers (eg Cdkn1a, Cdkn2a) is lower.
[0298] Biomechanical testing shows increased breaking strength and overall improvement in biomechanical parameters in the treatment groups.
[0299] c.In vitro evaluation: In aged HDFs, the treatment promotes ECM production, prevents ECM turnover, and inhibits oxidative stress.
[0300] In aged keratinocytes, treatment improves proliferation capacity, reduces collective cellular senescence, and promotes skin hydration / moisture.
[0301] In the above tests, E4 is effective at lower concentrations than E2, or is as effective as E2 at equivalent concentrations.
[0302] Example 11: Clinical study evaluating the effect of estetrol treatment on skin parameters in menopausal women A randomized, double-blind, placebo-controlled, Phase II study (pilot trial) will be conducted to evaluate the effect of estetrol in menopausal women and its effect on skin parameters.
[0303] The objective of this clinical trial is to further evaluate the clinical effects on collagen content, moisturization, elasticity, and other properties (e.g., skin thickness, wrinkling, roughness, and volume) and histological changes of the skin under menopausal hormone replacement therapy (MHT).
[0304] Study design This randomized, double-blind, placebo-controlled, Phase II study will consist of gynecological and dermatological investigations, which will be conducted at two different clinical sites specializing in each field.
[0305] If the subject is deemed suitable, an immediate dermatological screening will be performed at the CRC within 3 days. Subjects will be randomly assigned to one of two treatment groups and will receive E4 monohydrate 20 mg or placebo orally.
[0306] Women with NH should also be given progesterone according to this treatment regimen: Week 1 to Week 10: E4 Weeks 11-12: Simultaneous administration of E4 and P4 Weeks 13 to 22: E4 Weeks 23-24: Simultaneous administration of E4 and P4
[0307] Health improvement is assessed globally by a physician using the Clinical Global Impression scale (CGI).
[0308] Dermatological examination will include various biophysical measurements, assessment of skin condition, and analysis of skin biopsies. Measurements and evaluations will be performed at baseline (screening), 3-month and 6-month visits (dermatology visits). Skin biopsies will be taken at baseline and 6 months.
[0309] In addition, subjects will complete a menopause-specific quality of life (MENQoL) and a dermatology life quality index (DLQI) (DLQI will be completed by CRC at each dermatology visit).
[0310] Subject safety will be assessed throughout the study period.
[0311] Efficacy variables Efficacy variables for menopausal hormone replacement (MHT): Evaluation of the effect of laboratory tests on bone turnover by CGI evaluation
[0312] In addition, subjects will complete a menopause-specific quality of life (MENQoL) and a dermatology QoL (Dermatology Life Quality Index (DLQI)) questionnaire.
[0313] Dermatological Efficacy Variables: Dermatological investigations include various biophysical measurements, assessment of skin condition, and analysis of skin biopsies. Measurements and evaluations are performed at baseline (screening), typically at 3-month and 6-month visits. Skin biopsies are typically taken at baseline and 6-month visits. Safety of estetrol (E4) is evaluated throughout the study period in all subjects. Improvement in health is assessed globally by a physician using the Clinical Global Impression scale (CGI).
[0314] the last stop: The effect of E4 on overall skin texture, quality and appearance, and more specifically on skin thickness and collagen content, is analyzed.
[0315] The effect of E4 on skin moisturization, elasticity, water loss, epidermal thickness, dermal thickness, and sebum content is analyzed.
[0316] The top dermatological efficacy variables were: Measuring skin roughness. Measuring skin elasticity.
[0317] The others are considered secondary variables.
[0318] Secondary dermatological efficacy variables were: Skin moisturization analysis. Analysis of collagen content.
[0319] Skin parameters are assessed using the following non-invasive skin measurements: Moisturization of the stratum corneum (SC) by Corneometry (Corneometer™ CM 825, Courage & Khazaka) Skin elasticity by Cutometry (Cutometer™ MPA 580, Courage & Khazaka) Skin thickness by sonography (DermaScan™ C, Cortex technology) VISIA integrated PRIMOS CR-System for roughness, wrinkles and volume analysis
[0320] Skin measurements will be taken at different body sites at baseline and after 3 and 6 months: Skin biopsy: upper arm (inner) (2) Corneometry: Upper arm (inner) (1) Cutometry: upper arm (medial) and right ramus of mandible (1) Ultrasound measurement: upper arm or forearm (inner side) (1) VISIA skin analysis: face
[0321] Skin biopsies (4 mm punch circle biopsies) will be taken from the upper arm or inner forearm (same site as for ultrasound measurements) to: Analysis of collagen content at baseline and after 6 months, and measurement of dermal thickness on the inner upper arm. Analysis will be performed at CRC. Analysis of E4 after 6 months
[0322] Assessment of skin condition should include parameters of dryness (1).
[0323] (1)Sator PG, Sator MO, Schmidt JB, Nahavandi H, Radakovic S, Huber JC, Hoenigsmann H. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Climacteric. 2007 Aug;10(4):320-34. doi: 10.1080 / 13697130701444073.
[0324] (2)AV Sauerbronn 1, AM Fonseca, VR Bagnoli, PH Saldiva, JA Pinotti. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J. Gynaecol Obstet. 2000 Jan;68(1):35-41. doi: 10.1016 / s0020-7292(99)00166-6
[0325] Additionally, the following can be assessed: tightness, desquamation, sagging, telangiectasia, turgor, firmness, elasticity, moisture content, sebum production (greasiness), vascularization, and pigmentation. Additionally, the DLQI is answered by the subject.
[0326] Target population: Eligible subjects were hysterectomized and non-hysterectomized menopausal women aged 40-65 years.
[0327] Safety variables: Medical and gynecological history Physical Examination Gynecological examination Breast Examination Dermatological examination of the skin at CRC Vital signs ECG PAP Test TVUS (for endometrial thickness (excluding fibroids or polyps)) Laboratory Testing: Blood collection for the following purposes: Hematology / Chemistry Lipid / glucose parameters for participation FSH and E2 (to confirm untreated menopausal status), and TSH for participation E4 to ensure compliance during inspections Bone turnover Prior and concomitant medications will be identified and monitored throughout the study period. Adverse events (AEs) will be identified and monitored throughout the study period.
[0328] Diagnosis and Inclusion Criteria: Subjects preferably meet the following inclusion criteria at the time of the randomization visit: These criteria will be assessed during the screening period. 1. Females aged ≥40 years and ≤65 years at screening; 2. For subjects with a hysterectomy: A documented hysterectomy must have occurred at least 6 weeks prior to the start of screening. The hysterectomy can be total or subtotal (i.e., without removal of the cervix); 3.For non-hysterectomized subjects: the thickness of two layers of endometrium is 4 mm or less on transvaginal ultrasound (TVUS); 4. Seeking treatment to alleviate VMS associated with menopause; 5. Body mass index is 18.5 kg / m 2 More than 35.0 kg / m 2 below; 6. No significant signs of disease on mammograms taken during screening or within 9 months prior to starting screening 1 ; 7. Postmenopausal status defined as any of the following: a. For non-hysterectomized subjects: At least 12 months after natural menopause or 6 months after natural menopause with a serum FSH level >40 mIU / ml and an E2 level <20 pg / ml as measured by LC-MS (obtained after withdrawal of estrogen / progestin-containing medications) or 6 weeks after bilateral oophorectomy2 with or without hysterectomy; b. Regarding hysterectomy eligibility: serum FSH >40 mIU / mL (value obtained after withdrawal of estrogen / progestin-containing medications (if applicable), see exclusion criteria 18 and 20); Or 6 weeks after bilateral oophorectomy 2 ; 8. Good physical and mental condition, in the judgment of the responsible physician, based on medical history, physical and obstetric-gynecologic examination, and clinical evaluation prior to Visit 1; 9.Able to understand and comply with protocol requirements, instructions, and limitations stated in the protocol; 10. Be able to complete and cooperate with the examination diary and questionnaire. 11. Non-smoker (including e-cigarettes) for at least 1 year.
[0329] In addition, inclusion criteria taking into account skin conditions could be as follows: 1. Healthy skin in the measurement and biopsy area with sufficient hair-free area for measurement. 2. Fitzpatrick skin types I-IV. 3. Cooperate in using the same skin care products during the study. 4. Have psoriasis 5. Have sensitive skin
[0330] Subjects will not be assigned to treatment if they meet one of the following exclusion criteria: 1. History of malignancy, except for basal cell carcinoma or nonmetastatic squamous cell carcinoma, if diagnosed >1 year prior to the screening visit 3 ; 2. The investigator finds any clinically significant findings on breast examination and / or mammography that are suspicious for breast cancer, which may require further clinical investigations to eliminate the cancer (but simple cysts confirmed by ultrasound are acceptable); 3. PAP testing with atypical squamous cells of undetermined significance (ASC-US) or worse (low-grade squamous intraepithelial lesion [LSIL], atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion [HSIL] [ASC-H], HSIL atypia or malignant cells) in partial hysterectomized and nonhysterectomized subjects 5 NOTE: ASC-US is acceptable if reflex human papillomavirus (HPV) testing is performed and negative for high-risk oncogenic HPV subtypes 16 and 18; 4. Regarding non-hysterectomy subjects: a. History or presence of uterine cancer, endometrial hyperplasia; B. Presence of endometrial polyps c. Undiagnosed vaginal bleeding or undiagnosed abnormal uterine bleeding d. Endometrial ablation; e. Uterine / endometrial abnormalities that contraindicate the use of estrogen and / or progestin therapy in the opinion of the investigator, including the presence or history of adenomyosis or significant fibroids. 5. Systolic blood pressure (BP) > 139 mmHg and diastolic BP > 89 mmHg during screening 5 ; 6. History of venous or arterial thromboembolism (e.g., superficial or deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction, angina pectoris, etc.) or a first-degree family history of VTE; 7. History of known acquired or congenital coagulation disorders or abnormal coagulation factors (including thrombophilia); 8. Laboratory test results show fasting glucose >125 mg / dL and / or glycated hemoglobin >7%. 6 ; 9. Dyslipoproteinemia (LDL > 190 mg / dL and / or triglycerides > 300 mg / dL) 7 ; 10. Presence or history of gallbladder disease (except for those who have had a cholecystectomy); 11. Systemic lupus erythematosus; 12. Any malabsorption disorder, including gastric bypass surgery; 13. History of acute liver disease within 12 months prior to screening, or presence or history of chronic or severe liver disease [alanine transaminase (ALT) or aspartate transaminase (AST) >2x upper limit of normal (ULN), bilirubin >1.5x ULN] or liver tumor; 14. Chronic or current acute renal dysfunction (estimated glomerular filtration rate <60 ml / min); 15. Positive human immunodeficiency virus (HIV), hepatitis B, or hepatitis C serology; 16. Porphyria; 17. Diagnosis or treatment of major psychiatric illness (e.g., schizophrenia, bipolar disorder, etc.) in the judgment of the responsible physician; 18. Use of the following estrogen / progestin-containing drug(s): For vaginal and facial nonsystemic hormonal products (rings, creams, gels), 1 week prior to the start of screening; b. For vaginal or transdermal estrogen or estrogen / progestin products with systemic effects, 8 weeks prior to the start of screening; c. For oral estrogen and / or progestin products, and / or selective estrogen receptor modulator therapy, 8 weeks prior to the start of screening; d. for intrauterine progestin therapy, 8 weeks prior to screening; e. Progestin implant or estrogen-only injectable pharmaceutical therapy within 3 months prior to screening; f. estrogen pellet therapy or progestin injectable pharmaceutical therapy, 6 months prior to screening; 19. Use of Androgen / DHEA-Containing Medications: For oral, topical, vaginal, or transdermal androgens, 8 weeks prior to the start of screening; b. For implantable or injectable androgen therapy, 6 months prior to screening; 20. Use of phytoestrogens or black cohosh for the treatment of VMS within 2 weeks prior to screening; 21. Not cooperating with the discontinuation of all hormonal products listed in Exclusion Criteria 18, 19 and 20 during study participation; 22. Inadequately treated thyroid dysfunction. Subjects with low or high TSH are acceptable as long as free T4 is within reference range at screening. 8 . 23. History or presence of allergy / intolerance to the investigational product or to this class of drug or any component thereof, or history of drug or other allergy which in the opinion of the responsible physician contraindicates the subject's participation; 24. History of alcohol or drug abuse (including marijuana (even if legal)) or dependence during the 12 months prior to screening, as determined by the investigator based on reported observations; 25. Employees of the sponsor or CRO, or employees under the direct supervision of the Investigator and / or directly involved in the study; 26. Subject with known or suspected history of chronic systemic disease, unstable medical illness, life-threatening illness, or current malignancy that, in the opinion of the Investigator, would pose a risk to the subject; 27. Participated in a clinical trial of another investigational drug within 1 month (30 days) or received an investigational drug within 1 month (30 days) prior to the start of screening; 28. Deemed ineligible by the investigator for any reason; 29. The patient is institutionalized due to a legal or regulatory directive; 30. Scheduled for surgery during the clinical trial;
[0331] Further exclusion criteria considering skin condition and skin biopsy: 31. Presence of any skin condition or staining (e.g., acne, sunburn, skin infection, hyperpigmentation, tattoos) that would interfere with measurement and biopsy; 32. Patients with other active skin diseases (e.g., urticaria, atopic dermatitis, psoriasis) or active skin infections that may interfere with the evaluation or place the patient at unacceptable risk at the discretion of the investigator; 33. Strong UV exposure (sun or artificial) to the measurement area is expected during the study. Subjects should avoid exposing the measurement area to direct sunlight or tanning devices (e.g. sunbeds) and should use sun protection products for the duration of the study; 34. Use of skin care products in the measurement area within 48 hours prior to the measurement visit (baseline, 3-month, and 6-month visits); 35. Use of any topical treatment on the arms or face (including but not limited to topical hyaluronan, topical immunomodulators, topical corticoids, retinoids) within 4 weeks of baseline that may have an effect on clinical assessment or biophysical measures, or use of systemic immunosuppressants or corticosteroids within 4 weeks of baseline. 36. Known predisposition to keloid or hypertrophic scar formation. 37. History of anaphylaxis or allergy to lidocaine (or any amide anesthetic); 38. Any treatment that may affect blood clotting and hemostasis (anticoagulants, acetylsalicylic acid, etc.) for 10 days prior to and up to 3 days after the PAP test procedure at screening. Low dose acetylsalicylic acid is permitted.
[0332] 3 The only exclusions are basal cell carcinoma or nonmetastatic squamous cell carcinoma of the skin, either of which was diagnosed >1 year prior to the subject's screening. 4 As indicated in writing within 18 months prior to screening or by the time of testing at screening. 5BP measurements may be repeated at screening if values remain outside the inclusion criteria after an additional 5-10 minutes of sitting. The last measured value is used to determine eligibility. Subjects with mild-to-moderate hypertension controlled on a stable antihypertensive regimen may be enrolled at the discretion of the investigator if they meet all inclusion / exclusion criteria. Subjects using methyldopa- or clonidine-containing antihypertensive medications will not be included. 6 Laboratory values of fasting glucose and glycosylated hemoglobin assessed over the past 6 months, as well as during drug withdrawal and screening, must be considered. 7 Subjects using lipid-lowering therapy must be on a stable dose for at least 1 month prior to screening and may be enrolled at the discretion of the investigator if they meet all inclusion / exclusion criteria. 8 A reflex T4 test should be performed at screening only if the screening TSH is outside the normal range.
[0333] Drawing translation Figure 1 Acellular area covering (% relative to theacellular area at t=0h) Figure 2 Acellular area covering (% relative to theacellular area at t=0h) Figure 3 Acellular area covering (% relative to theacellular area at t=0h) Figure 4 Acellular area covering (% relative to theacellular area at t=0h) Figure 5 Acellular area covering (% relative to theacellular area at t=0h) Figure 6 Acellular area covering (% relative to theacellular area at t=0h) Figure 7 Acellular area covering (% relative to theacellular area at t=0h) Figure 8 Acellular area covering (% relative to theacellular area at t=0h) Figure 9A Vehicle Mouse Fibloblasts %closure %closure Veh Vehicle Figure 9B Vehicle Human Fibroblasts %closure %closure V Vehicle Figure 10 Vehicle Figure 11A Human monocytes M1 Veh M1 Vehicle Figure 11B Mouse BMDM M0 Veh M0 Vehicle M1 Veh M1 Vehicle Figure 12 Cell seeding Test item application Test item or references Quantification of IL-6 and TNFα release by ELISA assays Cell viability assessment by MTS assay Figure 13 Untreated control no induction Dexa Dexamethasone Induction PMMA and calcium ionophore Figure 14A Mini pump (E2 / E4 / Veh) Non-invasive evaluation (eg ultrasound) Wounding wound End-point sample collection Day Number of days Figure 14B Epidermis epidermis Dermis Subcutis subcutaneous tissue Non-invasive ultrasound Histology & immunohistochem Histology & immunohistochemistry Breaking strength & elasticity Figure 15A Control COL III Collagen III COL I Collagen I
Claims
1. An oral dosage unit comprising an estetrol component in an amount equivalent to about 10 mg to about 25 mg of estetrol (E4) for use in improving or maintaining skin quality and / or skin appearance.
2. A method for improving or maintaining skin quality and / or skin appearance comprising oral administration (or ingestion) of an estetrol composition in a daily amount equivalent to about 10 mg to about 25 mg of estetrol.
3. 2. Use of an estetrol component in a daily oral dose equivalent to about 10 mg to about 25 mg of estetrol for the manufacture of a medicament for improving or maintaining skin quality and / or skin appearance.
4. 4. An oral dosage unit for use as claimed in claim 1, a method as claimed in claim 2, or a use as claimed in claim 3, wherein improving or maintaining skin quality and / or skin appearance comprises alleviating the signs of skin aging, reversing the signs of skin aging, and / or reducing the signs of skin aging.
5. 5. The oral dosage unit for use, method or use according to claim 4, wherein said skin aging is hormone-related skin aging, more preferably skin aging due to menopausal hormone abnormalities such as estrogen deficiency (hypoestrogenism).
6. 6. An oral dosage unit for use, method or use according to any one of claims 1 to 5 in a subject diagnosed with or considered to be suffering from dermatoporosis.
7. 7. The oral dosage unit for use, method or use of claim 6, wherein the skin porous disease is characterized by decreased expression of collagen I, decreased expression of collagen III, decreased expression of collagen IV, increased expression of matrix metalloproteinase 1, increased expression of matrix metalloproteinase 2, increased expression of matrix metalloproteinase 3, decreased expression of matrix metalloproteinase I, decreased elastic tissue, defective collagen synthesis by fibroblasts, decreased hyaluronic acid, or any combination thereof.
8. 8. An oral dosage unit for use, method or use according to any one of claims 1 to 7, wherein the improving or maintaining of skin quality and / or skin appearance results in reduced release of interleukin-6, preferably reduced release of interleukin-6 when compared to a control condition in which estradiol is used.
9. 9. An oral dosage unit for use, method or use according to any one of claims 1 to 8, wherein the improvement or maintenance of skin quality and / or skin appearance is obtained by increasing keratinocyte function and / or growth in the skin, e.g. the epidermis.
10. 10. The oral dosage unit for use, method or use according to any one of claims 1 to 9, wherein the improving or maintaining of skin quality and / or skin appearance further increases fibroblast function, migration and / or fibroblast growth in the skin, or stimulates epithelial-mesenchymal interaction (EMI).
11. 11. The oral dosage unit for use, method or use according to any one of claims 1 to 10, wherein the improvement or maintenance of skin quality and / or skin appearance is characterized by any one or more effects selected from the group comprising: increased moisturization of the skin, e.g. by increasing the levels of glycosaminoglycans (in particular hyaluronic acid) in the skin and increasing hyaluronic acid synthase activity; increased sebum levels; and improved skin barrier function.
12. 12. An oral dosage unit for use, method or use according to any one of claims 1 to 11, wherein the improving or maintaining of skin quality and / or skin appearance is characterised by improved wound healing and / or reduced skin inflammation.
13. 13. The oral dosage unit for use, method or use according to any one of claims 1 to 12, wherein the improvement or maintenance of skin quality and / or skin appearance is characterized by any one or more effects selected from the group comprising: reduction of oxidative stress, e.g. by reducing ROS levels in the skin, and mitigating uneven skin pigmentation, such as the appearance of age spots.
14. 14. The oral dosage unit for use, method or use according to any one of claims 1 to 13, wherein the improvement or maintenance of skin quality and / or skin appearance is characterised by any one or more effects selected from the group comprising acne (pimples), skin rash and pruritus.
15. 15. An oral dosage unit for use, method or use according to any one of claims 1 to 14, wherein said improving or maintaining skin quality and / or skin appearance is characterised by the prevention, reduction of the effects or treatment of psoriasis in menopausal women.
16. 16. The oral dosage unit for use, method or use according to any one of claims 1 to 15, wherein a daily dose equivalent to about 14 mg to about 21 mg of estetrol, preferably about 14 mg to about 16 mg or about 19 mg to about 21 mg of estetrol, is administered.
17. 17. The oral dosage unit for use, method or use according to any one of claims 1 to 16, wherein the estetrol component is estetrol or an ester thereof, preferably the estetrol component is estetrol monohydrate.
18. 18. An oral dosage unit, method or use according to any one of claims 1 to 17, wherein the dosage unit does not contain a progestogen or no progestogen is used or co-administered.
19. 19. The oral dosage unit for use, method or use according to any one of claims 1 to 18, wherein a progestogen is present in the oral dosage unit or is used, is co-administered or is administered after treatment with estetrol, preferably the progestogen is selected from the group comprising progesterone, drospirenone, norethisterone, norethisterone acetate (NETA), dydrogesterone, levonorgestrel (LNG), etonogestrel, norgestrel, nomegestrol, nomegestrol acetate (NOMAC), trimegestone, nestorone, dydrogesterone, gestodene, desogestrel, norgestimate, cyproterone acetate, dienogest and chlormadinone, more preferably the progestogen is selected from the group comprising drospirenone, progesterone or dydrogesterone.
20. 20. The oral dosage unit for use, method or use according to claim 19, wherein the progestogen is present in the oral dosage unit in an amount equivalent to about 0.25 mg to about 4 mg, more preferably about 1 mg to about 4 mg, such as about 1 mg to about 3 mg, about 2.5 mg to 3.5 mg of drospirenone, or the progestogen is administered in an amount equivalent to about 2.5 mg to 3.5 mg of drospirenone.
21. An oral dosage unit, method or use according to any one of claims 1 to 20, wherein a further active ingredient suitable for improving or maintaining skin quality and / or skin appearance is present in the oral dosage unit or a further active ingredient suitable for improving or maintaining skin quality and / or skin appearance is co-administered or administered before or after treatment with estetrol.
22. 22. The oral dosage unit for use, method or use according to any one of claims 1 to 21, wherein the composition is formulated as an oral dosage unit for oral, sublingual, buccal or labial administration.
23. 23. The oral dosage unit, method or use according to any one of claims 1 to 22, wherein said oral dosage unit is formulated to correspond to a daily dosage unit or is administered as a daily dosage, respectively.
Citation Information
Patent Citations
A method of treating human skin and a skin care composition for use in such a method
WO2003103685A1
